NCT04648826
Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies treatment 1 / 2 withdrawn NCT03727087
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Melanoma No drug interventions Not Available Not Available terminated NCT00466687
Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma treatment 2 completed NCT04370587
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors treatment 1 / 2 recruiting NCT05196087
Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!) No drug interventions Not Available Not Available recruiting NCT03898687
The Use of Magtrace®/Sentimag® in Sentinel Node Biopsy for Malignant Melanoma. The Magmen Study. No drug interventions diagnostic Not Available completed NCT04698187
CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma treatment 2 completed NCT05973487
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors No drug interventions treatment 1 recruiting NCT02883933
Clinical and Histological Features of Head and Neck Melanoma No drug interventions Not Available Not Available completed NCT03163433
Feedback in the Consultation - a Dialogue-based Tool in Personalised Care Planning Using Systematic Patient Involvement No drug interventions supportive_care Not Available completed NCT02410733
Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma No drug interventions treatment 1 completed NCT04489433
Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma Not Available Not Available available NCT00972933
Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma treatment 0 completed NCT00846833
Haploidentical NK Cell Infusion in Malignant Melanoma No drug interventions treatment 1 / 2 completed NCT02838433
Study of Anti-telomerase T CD4 Immunity in Melanoma No drug interventions Not Available Not Available unknown_status NCT01959633
Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation treatment 1 / 2 completed NCT01622933
Multiple Antigen-Engineered DC Vaccine for Melanoma treatment 1 completed NCT05600933
Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment No drug interventions Not Available Not Available enrolling_by_invitation NCT00062933
A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma No drug interventions treatment 2 completed NCT04013854
Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab treatment 2 recruiting NCT00671554
Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma No drug interventions treatment 1 / 2 terminated NCT00423254
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. No drug interventions treatment 1 completed NCT03101254
LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma treatment 1 / 2 completed NCT03379454
The Impact of Melanoma and Drug Treatment in the Real World No drug interventions Not Available Not Available completed NCT02083354
Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma treatment 2 completed NCT05180851
Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study No drug interventions treatment 0 unknown_status NCT03973151
Study of HL-085 in NRAS Mutant Advanced Melanoma treatment 1 / 2 completed NCT01474551
Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation treatment 2 terminated NCT04572451
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma treatment 1 recruiting NCT01400451
Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) treatment 1 terminated NCT02012751
Nevus Doctor Clinical Decision Support No drug interventions diagnostic Not Available completed NCT04977453
GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors treatment 1 / 2 recruiting NCT00094653
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma treatment 3 completed NCT01666353
PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy No drug interventions diagnostic 0 completed NCT02385253
Training Primary Care Physicians to Perform Melanoma Opportunistic Surveillance No drug interventions screening Not Available completed NCT00080353
Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma treatment 2 completed NCT01935453
A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer No drug interventions treatment 1 completed NCT03092453
Dendritic Cell Vaccination in Patients With Advanced Melanoma treatment 1 active_not_recruiting NCT02706353
APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma treatment 1 / 2 active_not_recruiting NCT00667953
Study of Temzolomide and Gleevec in Advanced Melanoma treatment 1 / 2 terminated NCT04929353
SYSTEMATIC SYMPTOM ASSESSMENT IN CANCER PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS No drug interventions prevention Not Available unknown_status NCT03891953
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. treatment 1 active_not_recruiting NCT03932253
MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b) No drug interventions treatment 1 suspended NCT03652077
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies treatment 1 completed NCT04837677
A Study of PRT1419 in Patients With Advanced Solid Tumors No drug interventions treatment 1 completed NCT05539677
Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research No drug interventions Not Available Not Available recruiting NCT03338777
Suicide Plus Immune Gene Therapy for Advanced Melanoma No drug interventions treatment 0 terminated NCT00001577
Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity No drug interventions treatment 1 completed NCT04695977
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma treatment 2 / 3 completed NCT04993677
A Study of SEA-CD40 Given With Other Drugs in Cancers treatment 2 active_not_recruiting NCT01972347
Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma treatment 2 active_not_recruiting NCT01773447
Set-back Suture Versus Traditional Vertical Mattress Suture No drug interventions supportive_care Not Available completed NCT02507947
SPECTAmel: Screening Patients With Melanoma Tumors for Efficient Clinical Trial Access No drug interventions Not Available Not Available withdrawn NCT06305247
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours No drug interventions treatment 1 / 2 recruiting NCT03050047
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors No drug interventions treatment 1 unknown_status NCT04407247
Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma treatment 1 / 2 recruiting NCT05078047
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients With Metastatic Cancer in Response After 6 Months of Standard IO No drug interventions treatment 3 recruiting NCT03872947
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors treatment 1 recruiting NCT06207747
Quantitative Analysis of PET/CT Images of Immune Related Side Effects in Metastatic Melanoma Patients No drug interventions diagnostic Not Available active_not_recruiting NCT04035447
Symptom Management for YA Cancer Survivors No drug interventions supportive_care Not Available completed NCT00776945
Feasibility and Functionality of fPAM Imaging in Melanoma No drug interventions Not Available Not Available terminated NCT01859845
Melanoma Simulation Model With Smartphone Devices: Training Physicians for Early Detection of Melanoma No drug interventions screening Not Available completed NCT02983045
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors treatment 1 / 2 completed NCT02828345
Bio-marker Analysis Using Circulating Tumor Cells in Patients With Melanoma No drug interventions Not Available Not Available withdrawn NCT02711345
A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers. treatment 1 terminated NCT02862145
Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions treatment 1 / 2 withdrawn NCT00733798
A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma treatment 1 / 2 terminated NCT00001898
Microarray Analysis for Human Genetic Disease No drug interventions Not Available Not Available completed NCT00581698
Intraoperative Mapping of Regional Lymphatics Draining the Primary Site of Melanoma Using Isosulfan Blue No drug interventions Not Available Not Available completed NCT01530698
Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients No drug interventions treatment 1 / 2 completed NCT04835805
A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. treatment 1 active_not_recruiting NCT00482105
Early Diagnosis of Melanoma Using Expression Profiling and Non-Invasive Sampling of Skin Cells No drug interventions diagnostic Not Available terminated NCT02153905
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive treatment 1 / 2 terminated NCT04291105
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients treatment 2 recruiting NCT01776905
In Vivo Real-time Detection of Circulating Melanoma Cells No drug interventions Not Available Not Available active_not_recruiting NCT05955105
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies treatment 1 / 2 recruiting NCT03052205
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors treatment 1 completed NCT02437305
Melanoma Perception and Health Literacy in People of Color No drug interventions prevention Not Available completed NCT05732805
A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma treatment 3 recruiting NCT02823405
X4P-001 and Pembrolizumab in Patients With Advanced Melanoma treatment 1 completed NCT03448497
Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom No drug interventions Not Available Not Available completed NCT01740297
Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma treatment 1 / 2 completed NCT00254397
Melanoma Vaccine With Peptides and Leuprolide prevention 2 completed NCT05012397
Milademetan in Advanced/Metastatic Solid Tumors treatment 2 terminated NCT06221397
Clinical Validation Study of an AI-based CAD System for Early Non-Invasive Detection of Cutaneous Melanoma No drug interventions Not Available Not Available recruiting NCT00042497
Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma No drug interventions treatment 2 suspended NCT00492297
A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma treatment 2 completed NCT04761783
BESPOKE Study of ctDNA Guided Immunotherapy No drug interventions Not Available Not Available completed NCT02961283
Study of ASN003 in Subjects With Advanced Solid Tumors No drug interventions treatment 1 terminated NCT05470283
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma treatment 1 active_not_recruiting NCT05615883
Effects of Acute and Chronic Exercise on Myeloid-Derived Suppressor Cells in Melanoma Patients No drug interventions other Not Available unknown_status NCT02406183
Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma treatment 1 completed NCT02113683
Validation of MMS Test for Cancer Monitoring No drug interventions Not Available Not Available terminated NCT04930783
NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma treatment 1 recruiting NCT03958383
IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma treatment 1 / 2 suspended NCT05238883
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors treatment 1 recruiting NCT05488483
A Study of Tumor Imaging With Multispectral Optoacoustic Tomography No drug interventions Not Available Not Available active_not_recruiting NCT02922283
IL2 Imaging in Metastatic Melanoma No drug interventions diagnostic Not Available terminated NCT00409383
Abraxane and Temodar Plus Genasense in Advanced Melanoma treatment 1 unknown_status NCT03123783
CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab treatment 1 / 2 completed NCT00515983
Vaccination of Melanoma Patients With Dendritic Cells Loaded With Allogeneic Apoptotic-Necrotic Melanoma Cells No drug interventions treatment 1 completed NCT02180061
Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041) treatment 1 completed NCT00965861
SCRI Tissue Testing Registry No drug interventions Not Available Not Available terminated NCT03370861
How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes No drug interventions Not Available Not Available terminated NCT01078961
An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma treatment 1 completed NCT02493361
Trial of pIL-12/MK-3475 in Metastatic Melanoma treatment 2 completed NCT00707161
Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma treatment 2 terminated NCT03126461
SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients treatment 2 withdrawn NCT02763761
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo treatment 2 withdrawn NCT02352428
Skin Cancer Screening Education Study No drug interventions screening Not Available unknown_status NCT00722228
Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors No drug interventions prevention 1 / 2 unknown_status NCT03617328
Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma treatment 1 / 2 completed NCT05225428
Video Education With Result Dependent dIsclosure No drug interventions health_services_research Not Available recruiting NCT06080711
AI-Augmented Skin Cancer Diagnosis in Teledermatoscopy No drug interventions diagnostic Not Available enrolling_by_invitation NCT01827111
Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma treatment 2 completed NCT02301611
Phase IIB TL + YCWP + DC in Melanoma No drug interventions treatment 2 completed NCT01639911
Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors treatment 1 completed NCT06326411
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors No drug interventions treatment 1 recruiting NCT05961111
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors No drug interventions treatment 0 recruiting NCT02057393
Infrared Lymphangiography as a Method of Sentinel Node Identification diagnostic Not Available completed NCT00765193
The Impact of Total Body Skin Examination on Skin Cancer Detection No drug interventions diagnostic Not Available completed NCT01551693
STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma treatment 2 terminated NCT01942993
The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma treatment 2 terminated NCT00791271
Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion treatment 1 terminated NCT01772771
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program No drug interventions Not Available Not Available recruiting NCT01356771
Melanoma Risk Assessment & Tailored Intervention No drug interventions supportive_care Not Available completed NCT05366478
A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors treatment 1 recruiting NCT06172478
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors No drug interventions treatment 2 recruiting NCT04123678
DERM Health Economics Study No drug interventions Not Available Not Available completed NCT02403778
Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma treatment 2 completed NCT03881488
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies treatment 1 active_not_recruiting NCT06438588
Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial No drug interventions supportive_care Not Available recruiting NCT03282188
REO13 Melanoma With of Without GM-CSF basic_science 1 / 2 withdrawn NCT01152788
Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma treatment 2 completed NCT03822988
ACCEPTABILITY AND WRITING FREQUENCY OF ADVANCED DIRECTIVES IN ONCO-DERMATOLOGY PATIENTS No drug interventions Not Available Not Available unknown_status NCT00509288
Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes treatment 2 completed NCT05089188
PRAME Immunohistochemistry as an Adjunct for Evaluating Ambiguous Melanocytic Proliferation No drug interventions Not Available Not Available unknown_status NCT00184288
Proton MR Spectroscopy of Brain Metastases in Evaluation of Treatment Response. No drug interventions Not Available Not Available withdrawn NCT01496807
Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma treatment 1 completed NCT05235607
Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors No drug interventions treatment 1 unknown_status NCT05451407
Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma treatment 1 unknown_status NCT00432107
A Study to Assess APO866 for the Treatment of Advanced Melanoma treatment 2 completed NCT05428007
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma treatment 2 recruiting NCT00833807
Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver treatment 1 completed NCT00111007
A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma treatment 3 completed NCT04577807
LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma treatment 2 active_not_recruiting NCT00849407
Genetic Risk Factors and Acquired Oncogenic Mutations of Melanoma No drug interventions Not Available Not Available unknown_status NCT00598507
Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma treatment 2 completed NCT01944709
Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Patients With Inoperable Stage III and Stage IV Melanoma No drug interventions treatment 1 / 2 terminated NCT02966509
Engagement of Patients With Advanced Cancer No drug interventions health_services_research Not Available completed NCT02508909
Videoscopic Ilioinguinal Lymphadenectomy for Melanoma No drug interventions treatment Not Available completed NCT01272609
Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel treatment 3 unknown_status NCT04895709
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors treatment 1 / 2 recruiting NCT03787056
Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients No drug interventions diagnostic Not Available recruiting NCT04177056
Stereotactic Body Radiotherapy for Osseous Low Alpha-Beta Resistant Metastases for Pain Relief No drug interventions treatment Not Available unknown_status NCT03629756
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies treatment 1 completed NCT02498756
Cytokine-induced Killer Study for Patients With Stage II Melanoma treatment 2 not_yet_recruiting NCT03161756
Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma treatment 1 / 2 unknown_status NCT00044356
Phase II Trial of Allovectin-7® for Metastatic Melanoma No drug interventions treatment 2 completed NCT04193956
POINTING: Clinical Cohort Study of Patients With Melanoma and NSCLC Receiving Checkpoint Inhibitors No drug interventions Not Available Not Available recruiting NCT03941756
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma prevention Not Available recruiting NCT03665285
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors No drug interventions treatment 1 / 2 completed NCT05087485
Integrated Basic Science Within the Instructional Design of Pattern Recognition Training No drug interventions diagnostic Not Available completed NCT00001685
Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase treatment 2 completed NCT04749485
A Study of HX008 for the Treatment of Patients With Malignant Melanoma treatment 2 unknown_status NCT02089685
Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) treatment 1 / 2 completed NCT04157985
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors treatment 3 recruiting NCT00601185
Confocal Reflectance Microscopy of Shave-Biopsy Sites on Skin in Vivo. No drug interventions Not Available Not Available completed NCT01092585
Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH treatment 2 unknown_status NCT01584115
Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA) treatment 1 / 2 unknown_status NCT01331915
Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients No drug interventions treatment 1 / 2 unknown_status NCT00753415
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002) No drug interventions treatment 1 completed NCT01585415
Vemurafenib and White Blood Cell Therapy for Advanced Melanoma treatment 1 terminated NCT02719015
Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma treatment 1 / 2 withdrawn NCT01205815
Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment No drug interventions Not Available Not Available recruiting NCT01009515
Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma treatment 2 terminated NCT00368615
Characterization of the Melanoma-Specific Immune Response No drug interventions Not Available Not Available recruiting NCT00272415
A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma treatment 1 terminated NCT05234437
A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma treatment 2 terminated NCT05077137
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy treatment 1 recruiting NCT01321437
Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma treatment 2 completed NCT00379132
131-I-TM-601 Study in Adults With Solid Tumors treatment 1 completed NCT02112032
Treatment of Advanced Melanoma With MK-3475 and Peginterferon treatment 1 completed NCT02416232
Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma Not Available Not Available no_longer_available NCT03400332
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers treatment 1 / 2 active_not_recruiting NCT00735332
Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma treatment 2 terminated NCT03517332
Circulating Tumor DNA Exposure in Peripheral Blood No drug interventions Not Available Not Available unknown_status NCT05060432
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors treatment 1 / 2 active_not_recruiting NCT00040352
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma No drug interventions Not Available Not Available recruiting NCT00083252
Study of Talabostat and Cisplatin in Advanced Melanoma treatment 2 completed NCT04244552
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies treatment 1 terminated NCT02223052
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies treatment 1 completed NCT03480152
Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer No drug interventions treatment 1 / 2 terminated NCT00960752
Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist treatment 2 completed NCT06052852
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies treatment 1 / 2 recruiting NCT01006252
A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma treatment 3 terminated NCT00006200
Thalidomide and Dacarbazine for Metastatic Melanoma treatment 2 unknown_status NCT00591500
A Model for Genetic Susceptibility: Melanoma No drug interventions Not Available Not Available active_not_recruiting NCT01215500
Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer No drug interventions treatment 1 completed NCT05105100
Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma No drug interventions Not Available Not Available recruiting NCT00585000
A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma treatment 1 terminated NCT00698100
Vaccination of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Human and Mouse Tyrosinase DNA Vaccines treatment 1 completed NCT05483400
Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors treatment 2 recruiting NCT00029900
ADI-PEG in Patients With Metastatic Melanoma No drug interventions treatment 1 completed NCT02821000
Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151) treatment 1 completed NCT01256359
Docetaxel With or Without AZD6244 in Melanoma treatment 2 completed NCT02573259
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors No drug interventions treatment 1 completed NCT02721459
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma treatment 1 active_not_recruiting NCT04044859
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) No drug interventions treatment 1 recruiting NCT01489059
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma treatment 1 completed NCT04464759
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma treatment 1 / 2 recruiting NCT06295159
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma treatment 0 recruiting NCT05402059
Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice No drug interventions Not Available Not Available recruiting NCT00431275
Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody treatment 1 completed NCT02545075
A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine treatment 3 completed NCT04722575
Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma treatment 2 active_not_recruiting NCT01191775
A Study of PNT2258 in Patients With Advanced Solid Tumors treatment 1 completed NCT01009775
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma treatment 2 completed NCT00184275
Characterization of Brain Metastases No drug interventions Not Available Not Available completed NCT01611675
Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma treatment 1 terminated NCT00849875
A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients treatment 2 terminated NCT00099970
Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy treatment 2 completed NCT04397770
Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma treatment 2 unknown_status NCT06242470
A Study of MGC026 in Participants With Advanced Solid Tumors No drug interventions treatment 1 recruiting NCT04136470
BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics Not Available Not Available unknown_status NCT05457842
A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery diagnostic 2 terminated NCT00130442
Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma treatment 2 completed NCT02374242
Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases treatment 2 active_not_recruiting NCT01052142
Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma No drug interventions treatment 1 completed NCT05180942
Statins and prOgression of Coronary atheRosclerosis in melanomA Patients Treated With chEckpoint inhibitorS treatment 2 recruiting NCT04430842
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S No drug interventions treatment 1 completed NCT01200342
Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma treatment 2 terminated NCT00112242
Immunotherapy of Stage III/IV Melanoma Patients treatment 1 completed NCT01435499
Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma treatment 1 completed NCT05013099
Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies diagnostic 2 active_not_recruiting NCT02376699
Safety Study of SEA-CD40 in Cancer Patients treatment 1 terminated NCT04083599
GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors treatment 1 / 2 recruiting NCT02388906
Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma treatment 3 active_not_recruiting NCT03638206
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies No drug interventions treatment 1 / 2 unknown_status NCT00477906
M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma treatment 3 unknown_status NCT03565406
A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma treatment 1 terminated NCT00861406
Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine treatment 1 completed NCT04567706
A Storage Facility for Tissues Obtained From Patients With Malignant Melanoma No drug interventions Not Available Not Available recruiting NCT02983006
Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma treatment 1 completed NCT04427306
Neoadjuvant T-VEC in High Risk Early Melanoma treatment 2 suspended NCT06008106
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma treatment 3 recruiting NCT00518206
Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma treatment 2 completed NCT03336606
Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma treatment 1 active_not_recruiting NCT02009449
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors treatment 1 active_not_recruiting NCT02382549
A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib No drug interventions treatment 0 terminated NCT02681549
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer treatment 2 active_not_recruiting NCT02645149
Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma treatment 2 recruiting NCT03999749
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma treatment 2 active_not_recruiting NCT01425749
Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI No drug interventions treatment 0 completed NCT02307149
Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI) treatment 1 completed NCT03725449
Internet-based Intervention for Skin Self-Examination in Participants With Increased Risk for Melanoma No drug interventions prevention Not Available completed NCT02416336
Evaluation of Intraoperative Usage of Sentinella in Detecting Sentinel Lymph Nodes No drug interventions treatment Not Available completed NCT05858736
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors No drug interventions treatment 1 recruiting NCT02759536
In-hospital Neutron Irradiator (IHNI)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment of Malignant Melanoma No drug interventions treatment 1 / 2 unknown_status NCT00276536
Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma treatment 1 completed NCT02475213
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer treatment 1 completed NCT06199713
Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients No drug interventions Not Available Not Available recruiting NCT03139513
A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU]) Not Available Not Available completed NCT02671513
A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients treatment 1 unknown_status NCT05057013
HMBD-001 in Advanced HER3 Positive Solid Tumours No drug interventions treatment 1 / 2 recruiting NCT05539118
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma treatment 1 / 2 not_yet_recruiting NCT00107718
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma treatment 2 completed NCT06398418
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors No drug interventions treatment 1 not_yet_recruiting NCT02714218
A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma treatment 3 completed NCT04198818
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors No drug interventions treatment 1 / 2 terminated NCT00457418
High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2) treatment 1 completed NCT00671918
Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma treatment 3 completed NCT01390818
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors treatment 1 completed NCT04961619
Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma. Not Available Not Available recruiting NCT03878719
Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma treatment 1 terminated NCT00835419
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression No drug interventions treatment 2 completed NCT04851119
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors treatment 1 / 2 recruiting NCT04038619
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients treatment 1 recruiting NCT02511119
Application of Genomic Techniques and Image Processing Using Artificial Intelligence to Obtain a Predictor Model Risk of Melanoma No drug interventions Not Available Not Available unknown_status NCT01053819
Can We Miss Pigmented Lesions in Psoriasis Patients? treatment 4 completed NCT01866319
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006) treatment 3 completed NCT01876641
Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib treatment 1 terminated NCT03177941
Teaching Skin Self-Examination to First-degree Relatives of Melanoma Patients Using Mobile App Technology No drug interventions prevention Not Available withdrawn NCT03808441
CAcTUS - Circulating Tumour DNA Guided Switch No drug interventions treatment 2 active_not_recruiting NCT01079741
Safety Study of Adjuvant Vaccine to Treat Melanoma Patients treatment 1 / 2 completed NCT00588341
Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection treatment 2 completed NCT00281541
A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma treatment 2 completed NCT01272817
Nonmyeloablative Allogeneic Transplant No drug interventions treatment Not Available completed NCT03026517
Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma treatment 1 active_not_recruiting NCT05874817
Retrospective Assessment of AE-Related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma No drug interventions Not Available Not Available completed NCT01323517
Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity treatment 2 completed NCT05551117
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors treatment 2 active_not_recruiting NCT00005617
Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma No drug interventions treatment 1 completed NCT03159117
Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma No drug interventions treatment 1 completed NCT05426317
Exploratory Interventional Study of Prognostic Serum Biomarkers of Cancer Progression No drug interventions other Not Available unknown_status NCT00421317
Imatinib in Adult Patients With Metastatic Ocular Melanoma treatment 2 terminated NCT03520634
PD-L1 PET Imaging in Melanoma Patients No drug interventions diagnostic Not Available completed NCT00394134
Targeted Intervention for Melanoma Prevention No drug interventions prevention Not Available completed NCT04756934
A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma treatment 1 unknown_status NCT06101134
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations treatment 2 recruiting NCT03982134
PDR001 + Panobinostat for Melanoma and NSCLC treatment 1 withdrawn NCT01259934
Nordic Adjuvant IFN Melanoma Trial treatment 3 completed NCT05061134
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition treatment 2 active_not_recruiting NCT04334824
Hydrochlorothiazide and Risk of Skin Cancer Not Available Not Available completed NCT05786924
A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers No drug interventions treatment 1 recruiting NCT00124124
Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine No drug interventions treatment 1 completed NCT03948724
Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology No drug interventions prevention Not Available active_not_recruiting NCT04146324
An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia Not Available Not Available active_not_recruiting NCT02452424
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors treatment 1 / 2 terminated NCT02339324
Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b treatment 1 completed NCT01785316
The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases No drug interventions treatment 3 completed NCT02891616
18F-FLT PET Imaging in Patients With Advanced Melanoma screening 1 terminated NCT02015416
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer treatment 1 completed NCT01897116
A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma treatment 1 completed NCT02437916
Safety Study of AMG 228 to Treat Solid Tumors No drug interventions treatment 1 terminated NCT05062096
Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melanoma or as Adjuvant Therapy for High-risk of Recurrence No drug interventions other Not Available unknown_status NCT00275496
Multicenter Selective Lymphadenectomy Trial (MSLT) No drug interventions treatment 3 completed NCT00743496
A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma No drug interventions treatment 1 completed NCT00600496
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) treatment 1 active_not_recruiting NCT00509496
Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes treatment 2 terminated NCT01341496
Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal treatment 1 terminated NCT05259696
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) treatment 1 / 2 active_not_recruiting NCT05136196
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study treatment 2 suspended NCT03504696
Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced Melanoma No drug interventions Not Available Not Available completed NCT04068896
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy No drug interventions treatment 1 / 2 completed NCT05830058
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma No drug interventions treatment 2 recruiting NCT00636558
Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04) treatment 1 completed NCT03712358
PVSRIPO for Patients With Unresectable Melanoma treatment 1 completed NCT02320058
An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself treatment 2 completed NCT04604158
Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients No drug interventions supportive_care Not Available completed NCT01916135
PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative No drug interventions diagnostic 1 completed NCT02334735
A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence treatment 2 completed NCT03950635
Dietary Intervention in Patients With a History of Melanoma No drug interventions supportive_care 1 recruiting NCT03454035
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors treatment 1 recruiting NCT02423863
In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol® treatment 2 completed NCT06287463
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway No drug interventions treatment 1 / 2 recruiting NCT00588263
Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer No drug interventions Not Available Not Available withdrawn NCT02432963
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy treatment 1 active_not_recruiting NCT02111863
Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma treatment 2 terminated NCT02739386
Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases Not Available Not Available completed NCT01526486
Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer No drug interventions treatment Not Available completed NCT02036086
Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases treatment 2 active_not_recruiting NCT00083239
Study of Talabostat in Advanced Melanoma treatment 2 completed NCT05592639
VideoEndoscopic Radical Inguinal Lymphadenectomy for Penile Cancer No drug interventions other Not Available recruiting NCT02302339
A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma treatment 2 terminated NCT03755739
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors treatment 2 / 3 recruiting NCT00341939
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data No drug interventions Not Available Not Available completed NCT02447939
Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma treatment 1 withdrawn NCT02902822
Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo No drug interventions diagnostic Not Available completed NCT05003622
Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors treatment 1 completed NCT02178722
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers treatment 1 / 2 completed NCT00339222
Family Study of Melanoma in Italy No drug interventions Not Available Not Available completed NCT02155322
A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400) treatment 2 completed NCT02520622
Digital vs. Printed Photographs: Impact on Skin Self-Examinations No drug interventions supportive_care Not Available completed NCT03470922
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma treatment 2 / 3 active_not_recruiting NCT02974725
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma treatment 1 terminated NCT02662725
Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases treatment 2 completed NCT04913025
REduced Frequency ImmuNE Checkpoint Inhibition in Cancers treatment 2 recruiting NCT02760225
Pembrolizumab-PET Imaging No drug interventions diagnostic Not Available completed NCT00507325
Sample Collection From Melanoma Patients No drug interventions Not Available Not Available terminated NCT00937625
T-cell Based Immunotherapy for of Melanoma treatment 1 / 2 completed NCT06168825
Mind Over Matter for Black and African American Women: A Single Arm Trial Examining Feasibility and Acceptability of a Supportive Intervention No drug interventions Not Available Not Available active_not_recruiting NCT05538130
A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors treatment 1 recruiting NCT04364230
Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) No drug interventions treatment 1 / 2 completed NCT03285230
The French E3N Prospective Cohort Study No drug interventions Not Available Not Available active_not_recruiting NCT04526730
Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients treatment 2 active_not_recruiting NCT02307630
PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study No drug interventions diagnostic Not Available active_not_recruiting NCT05053230
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer No drug interventions supportive_care Not Available recruiting NCT01918930
Tissue Procurement Substudy for Participants in Study CP-MGA271-01 basic_science 1 terminated NCT05461430
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) No drug interventions Not Available Not Available recruiting NCT02909348
Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab Not Available Not Available completed NCT01223248
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy No drug interventions treatment 3 active_not_recruiting NCT02646748
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors treatment 1 completed NCT02910557
Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection No drug interventions Not Available Not Available recruiting NCT03325257
Post-ATU Study of Nivolumab No drug interventions Not Available Not Available completed NCT04655157
Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma treatment 1 / 2 terminated NCT06536257
Personalised Immunotherapy Platform No drug interventions Not Available Not Available recruiting NCT03512457
Skin Self-Examination Education During Mammography No drug interventions prevention Not Available completed NCT00610857
Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma other 2 completed NCT00559026
Phase I/II Study of Chemo-Immunotherapy Combination in Melanoma Patients No drug interventions treatment 1 completed NCT01003626
Interstitial Fluid Pressure (IFP) Pilot Study in Melanoma Patients No drug interventions treatment Not Available withdrawn NCT00923026
Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies No drug interventions Not Available Not Available enrolling_by_invitation NCT00495066
Compassionate Use Trial for Unresectable Melanoma With Ipilimumab Not Available Not Available no_longer_available NCT02159066
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma treatment 2 completed NCT02225366
Intratumoral Injections of LL37 for Melanoma No drug interventions treatment 1 / 2 completed NCT01067066
A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma treatment 1 terminated NCT02442466
Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma Not Available 0 terminated NCT03743766
Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting treatment 2 active_not_recruiting NCT05051865
To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma treatment 2 recruiting NCT04785365
Long-Term Follow-Up Study of Patients Receiving ATL001 No drug interventions other 2 terminated NCT05297565
A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection treatment 3 completed NCT02576665
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) treatment 1 terminated NCT00237965
The Use of Mole Mapping Diagrams to Increase Skin Self Examination Accuracy No drug interventions Not Available Not Available completed NCT04928365
Evaluation of Cytokine Biomarkers in Melanoma Patients During Immunotherapy No drug interventions diagnostic 2 unknown_status NCT06488365
In Vivo Liquid Biopsy of Melanoma (Cytophone) No drug interventions diagnostic Not Available not_yet_recruiting NCT02498665
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies treatment 1 completed NCT02694965
Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma No drug interventions Not Available Not Available completed NCT02457065
Skin Care Behaviors Among Melanoma Survivors and Their Families No drug interventions prevention Not Available completed NCT03452774
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry No drug interventions Not Available Not Available recruiting NCT05171374
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE Not Available Not Available recruiting NCT00816374
Tailored Intervention for Melanoma Patient's Families No drug interventions supportive_care Not Available completed NCT01264874
MelaViD: A Trial on Vitamin D Supplementation for Resected Stage II Melanoma Patients treatment 3 terminated NCT02893774
Longitudinal Study of Behavioral Changes, Economic and Sociological After CAncer No drug interventions other Not Available completed NCT03476174
Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma treatment 2 terminated NCT05264974
Novel RNA-nanoparticle Vaccine for the Treatment of Early Melanoma Recurrence Following Adjuvant Anti-PD-1 Antibody Therapy No drug interventions treatment 1 recruiting NCT00912574
Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38 treatment Not Available completed NCT03174574
Two Cancers, One Gene. Why Some People in Families Develop Melanoma or Pancreas Cancer, While Still Others Never Develop Cancer. No drug interventions Not Available Not Available completed NCT01528774
Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers No drug interventions Not Available Not Available completed NCT05902520
Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors No drug interventions treatment 1 recruiting NCT00580320
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma treatment 1 completed NCT02308020
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain treatment 2 completed NCT04021420
Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma treatment 1 / 2 unknown_status NCT04116320
Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors treatment 1 active_not_recruiting NCT06146920
Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation No drug interventions other Not Available recruiting NCT00975520
Neurotropic Melanoma of the Head and Neck No drug interventions treatment Not Available active_not_recruiting NCT00667082
NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma other 1 completed NCT00504582
Fibrin Melanoma Axillary Node Study in Patients With Melanoma treatment Not Available completed NCT04197882
Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma treatment 1 active_not_recruiting NCT03621982
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors treatment 1 terminated NCT04680182
Early Complications After Axillary and Inguinal Lymph Node Dissection in Stage III Melanoma Patients No drug interventions treatment Not Available completed NCT06099782
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) treatment 2 recruiting NCT04581382
Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma treatment 0 active_not_recruiting NCT05653882
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors treatment 1 recruiting NCT00378482
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued. treatment 2 completed NCT00623831
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen No drug interventions treatment 1 completed NCT03741231
18FDG-PET in Patients With Melanoma or NSCLC Treated With Immunotherapy No drug interventions Not Available Not Available completed NCT02012231
Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. treatment 1 terminated NCT01264731
Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma treatment 1 completed NCT01783431
Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells treatment 1 terminated NCT04725331
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors treatment 1 / 2 recruiting NCT01295931
Nuclear and Near-Infrared (NIR) Imaging in Melanoma diagnostic 1 completed NCT02470273
Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID) No drug interventions Not Available Not Available completed NCT04420273
Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access No drug interventions prevention Not Available completed NCT01462773
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma treatment 1 completed NCT05478473
Clinical Study of Chidamide Combined With Toripalimab in the Treatment of Advanced Melanoma treatment Not Available recruiting NCT03901573
High-Risk Skin Cancers With Atezolizumab Plus NT-I7 treatment 1 / 2 terminated NCT03109327
Investigating the Clinical Utility of the MDS No drug interventions Not Available Not Available completed NCT03472027
Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma treatment 1 completed NCT02437227
A Phase I, First in Man Study to Evaluate the Safety and Tolerability of a panRAF Inhibitor (CCT3833/BAL3833)in Patients With Solid Tumours No drug interventions treatment 1 completed NCT05812027
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors No drug interventions Not Available Not Available recruiting NCT00996827
Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma No drug interventions Not Available Not Available terminated NCT03241927
Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT) treatment 2 terminated NCT02907827
Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence. No drug interventions screening Not Available recruiting NCT02515227
Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab treatment 1 / 2 completed NCT04473027
BLood Groups as Biomarker to Optimize Odds of Response to Anti-PD-1 Drugs No drug interventions Not Available Not Available terminated NCT06508827
Pilot Trial of Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma treatment 2 not_yet_recruiting NCT01368276
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma treatment 3 completed NCT00961376
Vaccination of Melanoma Patients With Total or CD25-depleted Peripheral Blood Mononuclear Cell (PBMC) No drug interventions treatment 2 terminated NCT03002376
An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1) treatment 1 completed NCT01212276
A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma No drug interventions treatment 1 terminated NCT01754376
Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma treatment 2 terminated NCT04477876
Study of CD160, an Activating NK Cell Receptor, in Melanoma: a Potential Therapeutic Target? No drug interventions Not Available Not Available not_yet_recruiting NCT02465060
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) screening 2 active_not_recruiting NCT00356460
Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma treatment 1 completed NCT06034860
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types treatment 1 recruiting NCT05076760
MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer treatment 1 recruiting NCT05926960
A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma treatment 2 recruiting NCT02362594
Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054) treatment 3 active_not_recruiting NCT05520294
Evaluating the Effects of Cannabis Use and Circulating Cannabinoids on Tumor Infiltrating Lymphocytes in Malignant Melanoma No drug interventions Not Available Not Available active_not_recruiting NCT01308294
Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients treatment 1 / 2 terminated NCT02050594
Ipilimumab 12-month Intensive Pharmacovigilance Protocol Not Available Not Available completed NCT06566391
Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma treatment 2 active_not_recruiting NCT01657591
Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma treatment 1 completed NCT03348891
TNF in Melanoma Patients Treated With Immunotherapy No drug interventions other Not Available completed NCT00341991
Molecular Epidemiology of Cutaneous Malignant Melanoma No drug interventions Not Available Not Available completed NCT05561491
A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients treatment 2 withdrawn NCT06540391
A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients treatment 1 not_yet_recruiting NCT00062491
Study of Karenitecin (BNP1350) to Treat Malignant Melanoma treatment 2 completed NCT05608291
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery treatment 3 recruiting NCT01118091
Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M... treatment 2 completed NCT02884362
Prospective Melanoma Database No drug interventions Not Available Not Available recruiting NCT03289962
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors treatment 1 active_not_recruiting NCT01245062
GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma treatment 3 completed NCT00055562
Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma treatment 2 / 3 completed NCT01355562
Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer treatment 2 withdrawn NCT06413680
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies No drug interventions treatment 1 / 2 not_yet_recruiting NCT05299580
"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)" treatment 2 withdrawn NCT00818480
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155 treatment 2 completed NCT00889980
Melanoma Molecular Profiling Analysis No drug interventions Not Available Not Available completed NCT06470880
Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor Therapy No drug interventions treatment 2 not_yet_recruiting NCT00451880
Study of XL281 in Adults With Solid Tumors treatment 1 completed NCT05367180
The Impact of a Prevention Program on Sun Risks in Primary School in Tropical French Region No drug interventions prevention Not Available completed NCT00896480
Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma treatment 2 completed NCT01386580
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. treatment 1 / 2 completed NCT00112229
Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients No drug interventions treatment 1 completed NCT00536029
MicroRNA Expression and Function in Cutaneous Malignant Melanoma No drug interventions Not Available Not Available completed NCT04242329
Surgery of Melanoma Metastases After Systemic Therapy No drug interventions treatment 2 withdrawn NCT02731729
Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy treatment 2 completed NCT05119829
Melanoma: Genomic Profiles, Molecular Markers and Therapeutic Implications No drug interventions Not Available Not Available unknown_status NCT04576429
Immune Profiles Evolution Under Immunotherapy for Melanoma No drug interventions treatment Not Available recruiting NCT00091689
Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions No drug interventions treatment 1 completed NCT02780089
Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study No drug interventions Not Available Not Available completed NCT00046189
Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum No drug interventions Not Available Not Available completed NCT00680589
Patients With Mouse Tyrp2 DNA: A Phase I Trial to Assess Safety and Immune Response No drug interventions treatment 1 completed NCT01515189
Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab treatment 3 completed NCT01604889
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma treatment 1 / 2 terminated NCT02565992
Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA) treatment 1 completed NCT02650492
Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma No drug interventions treatment Not Available terminated NCT04899492
Evaluation of Different Smoking Cessation Protocols: Nicotine Replacement, Motivational Interviewing (MI), Cognitive Behavioural Therapy (CBT) or Hypnotherapy in Cancer Patients Scheduled for Surgery treatment Not Available active_not_recruiting NCT06566092
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants treatment 1 recruiting NCT05004792
Dermoscopy Augmented Histology Trial, a Randomized Controlled Trial No drug interventions diagnostic Not Available not_yet_recruiting NCT03638492
Trial of Surgical Excision Margins in Thick Primary Melanoma - 2 No drug interventions treatment Not Available completed NCT01531244
Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma treatment 1 / 2 withdrawn NCT01013844
Partner Assistance in Learning and Performing Skin Self-Examination No drug interventions prevention Not Available completed NCT02142244
Fluorescence Surgery for Sentinel Node Identification in Melanoma diagnostic Not Available unknown_status NCT05864144
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors treatment 1 / 2 recruiting NCT02870244
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes No drug interventions treatment 1 recruiting NCT01039844
Study of Weekly LOC-paclitaxel Injection for Melanoma treatment 1 terminated NCT06046144
Comparison of 3 in Vivo Microscopic Imaging Techniques for the Diagnosis of Pigmented Tumors No drug interventions Not Available Not Available completed NCT02807844
Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies treatment 1 / 2 completed NCT01366144
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction treatment 1 active_not_recruiting NCT02659540
Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma treatment 1 completed NCT02568267
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) treatment 2 active_not_recruiting NCT01065467
Panobinostat (LBH589) in Patients With Metastatic Melanoma treatment 1 completed NCT05837767
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue No drug interventions treatment Not Available recruiting NCT01586767
Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy No drug interventions treatment Not Available active_not_recruiting NCT04386967
OH2 Injection in Solid Tumors treatment 1 / 2 recruiting NCT00020267
Vaccine Therapy in Treating Patients With Metastatic Cancer treatment 1 completed NCT00184067
Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma treatment 2 terminated NCT03228667
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors treatment 2 active_not_recruiting NCT04731467
A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors treatment 1 / 2 active_not_recruiting NCT02393001
Analysis of Skin Lesions for Melanoma Presence by Volatile Spectroscopy Techniques No drug interventions Not Available Not Available completed NCT00199901
Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma treatment 2 completed NCT05355701
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. treatment 1 recruiting NCT03829501
Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer treatment 1 / 2 active_not_recruiting NCT01740401
CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma treatment 2 terminated NCT05104801
Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma treatment 2 unknown_status NCT02799901
Nivolumab Plus Radiotherapy in Advanced Melanoma treatment 2 completed NCT02285101
Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors treatment 1 completed NCT00924001
Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma treatment 1 / 2 terminated NCT03464604
Melanoma Accuracy Study; Phase 2 No drug interventions Not Available Not Available terminated NCT03073304
A Randomized Controlled Study Comparing Priming Solution Containing Crystalloid or Packed Red Blood Cells in Patients Treated With Isolated Limb Perfusion. treatment Not Available completed NCT04985604
Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors treatment 1 / 2 recruiting NCT05581004
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors treatment 1 recruiting NCT00940004
Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients No drug interventions treatment 1 / 2 completed NCT01123304
Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma No drug interventions treatment 1 terminated NCT00513604
Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma treatment 2 completed NCT00339404
Genetic Analysis of Familial Melanoma No drug interventions Not Available Not Available completed NCT02279004
A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care No drug interventions Not Available Not Available recruiting NCT06418204
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics No drug interventions Not Available Not Available not_yet_recruiting NCT05648604
Mentored Community Gardening for Individuals With Skin Cancer No drug interventions other Not Available active_not_recruiting NCT02575404
GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients treatment 1 completed NCT05094804
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents treatment 1 / 2 recruiting NCT00132704
An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation No drug interventions Not Available Not Available completed NCT05867004
Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma No drug interventions Not Available Not Available recruiting NCT02210104
Adoptive Therapy Using Antigen-Specific CD4 T-Cells treatment 1 withdrawn NCT00769704
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma treatment 3 completed NCT04370704
Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies treatment 1 / 2 active_not_recruiting NCT00261404
TNFerade™ Biologic Plus Radiation for Metastatic Melanoma Not Available 2 completed NCT01721772
Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma treatment 3 completed NCT01823172
Second Echelon Node Study With Methylene Blue No drug interventions basic_science Not Available completed NCT04187872
LITT and Pembrolizumab in Recurrent Brain Metastasis treatment 1 terminated NCT01894672
BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation treatment 2 completed NCT00091572
Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267) treatment 3 completed NCT03745872
SunSmart Intervention in Schools No drug interventions prevention Not Available completed NCT00068172
Study of PI-88 in Patients With Advanced Melanoma treatment 1 / 2 completed NCT04700072
Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02) treatment 1 / 2 active_not_recruiting NCT06154668
Profiling of Circulating Immune Cells to Uncover Response Signatures to Anti-PD1 Immunotherapy in Melanoma Patients No drug interventions Not Available Not Available recruiting NCT02045368
Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R treatment 1 completed NCT02890368
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides treatment 1 terminated NCT00043368
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) treatment 2 completed NCT04107168
Microbiome Immunotherapy Toxicity and Response Evaluation Not Available Not Available recruiting NCT02332668
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) treatment 1 / 2 recruiting NCT03611868
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors treatment 1 / 2 recruiting NCT02105168
Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment No drug interventions screening Not Available unknown_status NCT00785369
In Vivo Confocal Microscopy for Pigmented Lesion Diagnosis No drug interventions diagnostic Not Available completed NCT03696069
A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma No drug interventions Not Available Not Available completed NCT02385669
A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma treatment 1 / 2 terminated NCT04565769
Cognitive Function in Patients Treated for Metastatic Melanoma With Immune Checkpoint Inhibitors No drug interventions Not Available Not Available active_not_recruiting NCT01435369
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma treatment 2 completed NCT04504669
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours treatment 1 active_not_recruiting NCT05703269
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy No drug interventions supportive_care Not Available recruiting NCT00746746
A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma treatment 2 unknown_status NCT03329846
An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma treatment 3 completed NCT02196246
Moletest Clinical Study in Scotland No drug interventions Not Available Not Available completed NCT05091346
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors treatment 1 / 2 active_not_recruiting NCT00897312
Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease Not Available Not Available terminated NCT05839912
Excision of Lymph Node Trial (EXCILYNT) (Mel69) No drug interventions treatment Not Available recruiting NCT01603212
Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor treatment 1 completed NCT01681212
Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma treatment 2 completed NCT00429312
A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma treatment 1 / 2 completed NCT01986712
A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma No drug interventions Not Available Not Available unknown_status NCT06120712
A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of Advanced Melanoma (MIZAR-002) No drug interventions treatment 1 / 2 recruiting NCT00839410
Multicentric Cohort of Melanoma Patients in Ile de France Area No drug interventions Not Available Not Available completed NCT00723710
Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600) Not Available Not Available completed NCT02023710
Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma treatment 2 unknown_status NCT00790010
Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma treatment 1 completed NCT05645510
LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study No drug interventions Not Available Not Available recruiting NCT02970981
Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma treatment 2 completed NCT03897881
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) treatment 2 recruiting NCT04068181
Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07). treatment 2 completed NCT02452281
Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma treatment 1 / 2 withdrawn NCT04759781
MElanoma Research Lymph Node Prediction Implementation National_001 No drug interventions Not Available Not Available active_not_recruiting NCT05673681
Spanish Academy of Dermatology and Venereology (AEDV) Melanoma Registry No drug interventions Not Available Not Available recruiting NCT01387581
Does the Aid of MelaFind Affect Clinical Management Decisions No drug interventions Not Available Not Available completed NCT00716495
Safety and Pharmacodynamic Study of a New Formulation, AGI - 101H Vaccine in the Treatment of Advanced Melanoma No drug interventions Not Available 1 / 2 terminated NCT01621295
Assessing the Patient Experience in Cancer Care No drug interventions Not Available Not Available completed NCT00615095
Differential Risks for Melanoma: p16 and DNA Repair No drug interventions Not Available Not Available completed NCT00297895
Multicenter Selective Lymphadenectomy Trial II (MSLT-II) No drug interventions treatment Not Available completed NCT02836795
Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors treatment 1 unknown_status NCT02005614
A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection No drug interventions treatment Not Available terminated NCT00779714
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC treatment 3 unknown_status NCT02251314
Use of Exome Sequence Analysis and Circulating Tumour in Assessing Tumour Heterogeneity in BRAF Mutant Melanoma No drug interventions Not Available Not Available completed NCT05229614
Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease treatment 2 recruiting NCT05280314
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors treatment 2 recruiting NCT02381314
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer treatment 1 completed NCT00084214
STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma treatment 1 / 2 completed NCT03980314
A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection treatment 1 completed NCT00306514
Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients No drug interventions Not Available 1 / 2 completed NCT05661955
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors. treatment 1 / 2 recruiting NCT00324155
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma treatment 3 completed NCT02346955
Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) treatment 1 terminated NCT05446155
BioMEL- Diagnostic and Prognostic Factors in Melanoma. No drug interventions Not Available Not Available recruiting NCT05231655
Ex VIvo DEtermiNed Cancer Therapy No drug interventions Not Available Not Available recruiting NCT01984255
A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients treatment 1 terminated NCT02374255
Improving Goals of Care Discussion in Advanced Cancer Patients No drug interventions supportive_care Not Available completed NCT06054555
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma treatment 3 recruiting NCT04091750
Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma treatment 2 suspended NCT03683550
Comparing SLNE With or Without Preoperative Hybrid SPECT/CT in Melanoma No drug interventions treatment Not Available active_not_recruiting NCT01672450
A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma treatment 1 completed NCT02143050
Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients treatment 1 / 2 withdrawn NCT00518050
Health Behaviors, Surveillance, Psychosocial Factors, and Family Concerns No drug interventions Not Available Not Available completed NCT02111850
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive treatment 1 / 2 completed NCT03391050
A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma treatment 1 / 2 terminated NCT01585350
A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients treatment 1 completed NCT00495950
Prospective Measurement of Post-Treatment Lymphedema No drug interventions Not Available Not Available completed NCT05708950
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) treatment 1 / 2 recruiting NCT02457650
T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies treatment 1 unknown_status NCT03484923
Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma treatment 2 completed NCT03913923
Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma No drug interventions treatment 2 active_not_recruiting NCT02736123
Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone treatment 1 / 2 withdrawn NCT00001823
Evaluation for NCI Surgery Branch Clinical Research Protocols No drug interventions Not Available Not Available recruiting NCT05736523
Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA) No drug interventions Not Available Not Available active_not_recruiting NCT04493723
Serial Tumour Biopsies and Blood Biomarkers in Melanoma No drug interventions Not Available Not Available recruiting NCT05106023
To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma treatment 2 recruiting NCT03313323
Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma diagnostic 2 unknown_status NCT04996823
Axitinib + Ipilimumab in Advanced Melanoma treatment 2 recruiting NCT01967823
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer treatment 2 completed NCT00496223
A Phase I/II Study of Sunitinib and Dacarbazine treatment 1 / 2 terminated NCT03420508
Treating Patients With Melanoma and ALK Alterations With Ensartinib treatment 2 active_not_recruiting NCT06495008
Taste and Smell Dysfunction in Patients More Than Two Years After Start of Immune Checkpoint Inhibitor Therapy No drug interventions Not Available Not Available recruiting NCT01531608
Evaluation Of Mobile Gamma Camera Imaging For Sentinel Node Biopsy In Melanoma No drug interventions Not Available Not Available completed NCT01597908
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma treatment 3 completed NCT02263508
Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma treatment 3 terminated NCT03528408
Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma treatment 2 active_not_recruiting NCT01397708
Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma treatment 1 / 2 completed NCT05500508
Oral AMXT 1501 Dicaprate in Combination With IV DFMO treatment 1 / 2 suspended NCT01863108
Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma No drug interventions treatment 1 completed NCT02439008
Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response No drug interventions basic_science Not Available terminated NCT01973608
MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma No drug interventions treatment 2 terminated NCT00095108
Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer treatment 1 completed NCT02372708
Clinical Research on the Treatments on Advanced Malignant Melanoma by Combining in Situ Immunotherapy and Laser Therapy No drug interventions Not Available Not Available completed NCT00804908
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma treatment 2 completed NCT01782508
A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma treatment 2 unknown_status NCT06153238
A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma treatment 1 recruiting NCT06216938
RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis No drug interventions treatment 0 recruiting NCT05117138
Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors No drug interventions treatment 1 / 2 unknown_status NCT02190838
Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated Melanoma treatment 2 terminated NCT01174238
A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma treatment 2 completed NCT02906943
Ontario-wide Cancer TArgeted Nucleic Acid Evaluation No drug interventions Not Available Not Available recruiting NCT02775643
Molecular Analysis of Childhood and Adolescent Melanocytic Lesions No drug interventions Not Available Not Available recruiting NCT04955743
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma treatment 2 recruiting NCT00219843
Intralesional PV-10 Chemoablation of Metastatic Melanoma treatment 1 completed NCT01846143
Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies No drug interventions treatment 1 completed NCT04616443
OH2 Injection in Combination With HX008 for Melanoma. treatment 1 / 2 recruiting NCT03341143
Fecal Microbiota Transplant (FMT) in Melanoma Patients treatment 2 active_not_recruiting NCT02600143
Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy. No drug interventions Not Available Not Available completed NCT06414343
LATe TreatmENT Related Toxicity in Melanoma (LATENT) No drug interventions Not Available Not Available not_yet_recruiting NCT01556503
Sensitivity/Specificity Study of Non-invasive Imaging for Melanoma Diagnosis No drug interventions Not Available Not Available completed NCT02974803
Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases treatment 2 terminated NCT01266603
High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI treatment 2 completed NCT03321903
EPR Tumor Oximetry With CE India Ink No drug interventions Not Available Not Available terminated NCT00068003
Harvesting Cells for Experimental Cancer Treatments No drug interventions Not Available Not Available enrolling_by_invitation NCT02643303
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers treatment 1 / 2 completed NCT04658303
Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma Not Available Not Available recruiting NCT02310503
Spanish Registry of Mohs Surgery No drug interventions Not Available Not Available completed NCT05217303
HL-085 in NRAS-mutated Advanced Melanoma treatment 2 completed NCT00937690
Pilot Study of Infrared Imaging of Cutaneous Melanoma No drug interventions Not Available Not Available completed NCT01066390
A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma No drug interventions treatment 1 completed NCT02989064
MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers No drug interventions treatment 1 completed NCT04490564
Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma No drug interventions Not Available Not Available active_not_recruiting NCT04354064
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors No drug interventions Not Available Not Available recruiting NCT04146064
Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response No drug interventions Not Available Not Available recruiting NCT06448364
A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination treatment 1 active_not_recruiting NCT01820364
LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma treatment 2 terminated NCT00612664
Phase II, 2nd Line Melanoma - RAND Monotherapy treatment 2 completed NCT03455764
MCS110 With BRAF/MEK Inhibition in Patients With Melanoma treatment 1 / 2 completed NCT05340621
NAUTILUS: OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2) treatment 1 / 2 active_not_recruiting NCT00565721
A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis diagnostic 2 completed NCT00936221
Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients treatment 2 completed NCT04897321
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) treatment 1 recruiting NCT04417621
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma treatment 2 active_not_recruiting NCT02621021
A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab treatment 2 suspended NCT01777802
Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy No drug interventions Not Available Not Available active_not_recruiting NCT00510302
Melanoma Risk-Reduction Among Patients and Family Members No drug interventions Not Available Not Available completed NCT00050102
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma treatment 2 completed NCT00928902
Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma treatment 2 completed NCT00221702
PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial) treatment 3 completed NCT00623402
Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma treatment 2 completed NCT05645484
The Prognostic Value of 18F-PFPN PET Imaging in Patients With Malignant Melanoma Not Available Not Available unknown_status NCT02083484
Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030) Not Available Not Available no_longer_available NCT00104884
FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma treatment 2 terminated NCT02680184
Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy treatment 1 completed NCT02043184
Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR No drug interventions supportive_care Not Available completed NCT02068079
A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma treatment 1 withdrawn NCT06047379
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis treatment 1 / 2 recruiting NCT04028479
The Registry of Oncology Outcomes Associated With Testing and Treatment No drug interventions Not Available Not Available recruiting NCT03754179
Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma treatment 1 / 2 unknown_status NCT04261179
Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer diagnostic 4 unknown_status NCT02586987
A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours treatment 1 completed NCT02339987
Procure Tumor and Initiate Melanoma Tumor-Reactive Tumor Infiltration No drug interventions Not Available Not Available terminated NCT04594187
Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma No drug interventions treatment 2 recruiting NCT00258687
Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma No drug interventions treatment 1 completed NCT01409187
IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma treatment 1 / 2 withdrawn NCT00701987
Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma treatment 1 unknown_status NCT00871533
Pilot Study of IFN α2b for Melanoma Patients No drug interventions diagnostic 0 terminated NCT00832533
The Response of Serum 25-Hydroxyvitamin D to Incidental Ultraviolet Light Exposure No drug interventions Not Available Not Available completed NCT02574533
Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma treatment 1 completed NCT04596033
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy treatment 1 terminated NCT01673854
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma treatment 2 completed NCT04305054
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) treatment 1 / 2 recruiting NCT06275854
YASU Research Registry: For Young Adults With Cancer No drug interventions Not Available Not Available not_yet_recruiting NCT02949154
Elevated LDH Serum Levels and FDG-PET in Metastatic Melanoma Patients No drug interventions Not Available Not Available completed NCT03955354
PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma treatment 2 unknown_status NCT01048554
Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System treatment 2 completed NCT04172454
Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors treatment 1 / 2 completed NCT00026754
Eligibility Screening for the NIH Intramural Research Program Clinical Protocols No drug interventions Not Available Not Available enrolling_by_invitation NCT03983954
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors treatment 1 active_not_recruiting NCT04773951
A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors treatment 1 unknown_status NCT02501551
Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy treatment 2 unknown_status NCT06190951
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma treatment 2 / 3 not_yet_recruiting NCT00303251
Safety of TKI258 in Advanced/Metastatic Melanoma Subjects treatment 1 / 2 completed NCT01625351
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas treatment 1 completed NCT05388851
Education for Prevention of Melanoma in Hispanic Populations No drug interventions prevention 2 active_not_recruiting NCT04099251
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma treatment 3 active_not_recruiting NCT00383851
Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma treatment 2 unknown_status NCT01909453
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma treatment 3 active_not_recruiting NCT00521053
Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma treatment 2 completed NCT02058953
CNS and Extracranial Tumor Tissues, CSF, and Blood From Patients With Melanoma Brain Metastases No drug interventions Not Available Not Available completed NCT00743353
Exploratory, Phase 0 Study of Positron Emission Tomography (PET) Imaging Agent, F-18 RGD-K5 No drug interventions diagnostic 0 completed NCT05714553
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours treatment 1 / 2 recruiting NCT03797053
Ex Vivo Expansion of Circulating Tumor Cells as a Model for Cancer Predictive Pharmacology No drug interventions Not Available Not Available unknown_status NCT03048253
A Phase I-c Study of Recombinant GM-CSF Herpes Simplex Virus to TreatⅣ M1c No drug interventions Not Available Not Available unknown_status NCT01011153
Survey Study - Sensitivity Comparison Between MelaFind and Physician Group No drug interventions Not Available Not Available completed NCT05263453
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation treatment 2 recruiting NCT00574977
Safety Study of Modified Vaccinia Virus to Cancer treatment 1 completed NCT03798977
Preclinical Validation of New Anti-melanoma Compounds No drug interventions Not Available Not Available completed NCT02574377
myDC/pDC in Stage III Melanoma Patients No drug interventions treatment 1 / 2 completed NCT00200577
Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma No drug interventions treatment 3 completed NCT05933577
A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) treatment 3 recruiting NCT03167177
QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy treatment 1 / 2 withdrawn NCT01690377
Natural Dendritic Cell Vaccines in Metastatic Melanoma Patients No drug interventions treatment 1 completed NCT05130177
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma treatment 2 recruiting NCT05403177
Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O) No drug interventions Not Available Not Available recruiting NCT00338377
Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma treatment 2 active_not_recruiting NCT01009177
Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC) treatment 2 completed NCT00582647
Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract No drug interventions Not Available Not Available active_not_recruiting NCT06043947
Survival Monitoring in Russian Cancer Registries No drug interventions Not Available Not Available active_not_recruiting NCT02962947
MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients treatment 2 / 3 unknown_status NCT03352947
Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma treatment 2 completed NCT03328247
Achieving Self-directed Integrated Cancer Aftercare (ASICA) in Melanoma No drug interventions diagnostic Not Available completed NCT04550247
A Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in France No drug interventions Not Available Not Available active_not_recruiting NCT00977145
Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma No drug interventions treatment 1 terminated NCT00831545
Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064) treatment 2 completed NCT04410445
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence treatment 3 terminated NCT02543645
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer treatment 1 terminated NCT05121545
Proton Pencil Beam Scanning GRID for Treatment of Bulky Tumors No drug interventions treatment Not Available recruiting NCT00796445
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor treatment 3 terminated NCT00207298
18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology No drug interventions Not Available Not Available completed NCT00512798
Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma treatment 1 / 2 terminated NCT05697198
PRospective rEgistry OF Advanced Stage cancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine No drug interventions Not Available Not Available recruiting NCT05108298
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials No drug interventions health_services_research Not Available recruiting NCT02509598
A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping diagnostic 2 completed NCT06327698
Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure treatment 2 not_yet_recruiting NCT00588198
Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma No drug interventions Not Available Not Available completed NCT00109005
Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma treatment 2 completed NCT04583605
The Aim of This Study is to Demonstrat That Vacuum-assisted Closure Versus Conventional Wound Closure Enables to Diminish Local Complications After Lymph Node Dissection in Patients With Metastatic Skin Tumors No drug interventions Not Available Not Available unknown_status NCT00001705
Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence No drug interventions treatment 2 completed NCT01437605
Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC treatment 2 terminated NCT03715205
Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) treatment 4 completed NCT00405405
Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer treatment 1 completed NCT00257205
CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy treatment 3 completed NCT02074605
Cognitive Effects of Interferon in Patients With Melanoma Not Available Not Available completed NCT06285097
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors treatment 1 recruiting NCT05746897
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors treatment 1 recruiting NCT04017897
The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma treatment 2 unknown_status NCT03665597
Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555) treatment 1 completed NCT00342797
Retinoblastoma Biomarker Study No drug interventions Not Available Not Available completed NCT00116597
Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma No drug interventions treatment 1 / 2 completed NCT01682083
Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). treatment 3 completed NCT04714983
DNX-2440 for Resectable Colorectal Liver Metastasis No drug interventions treatment 1 suspended NCT03595683
Pembrolizumab and EDP1503 in Advanced Melanoma treatment 2 active_not_recruiting NCT00001683
A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer treatment 1 completed NCT03635983
A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma treatment 3 completed NCT06189261
Holistic Needs Assessments in Patients With Melanoma No drug interventions Not Available Not Available completed NCT04747561
Clinical Application of 18F-PEG3-FPN PET Imaging in Diagnosis and Staging of Malignant Melanoma diagnostic Not Available unknown_status NCT00597961
Health Communication in Families No drug interventions Not Available Not Available completed NCT06116461
Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response treatment 4 recruiting NCT02027961
Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone treatment 1 completed NCT00673361
Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma treatment 2 terminated NCT00515528
Vaccination Plus Ontak in Patients With Metastatic Melanoma treatment 2 terminated NCT05744128
CD8 Minibody Repeatability Study diagnostic 2 recruiting NCT02581228
Multi-Centre, Retrospective, Open Label Study, to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of Immunotherapy No drug interventions Not Available Not Available unknown_status NCT01092728
Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma treatment 2 terminated NCT02847728
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice No drug interventions Not Available Not Available completed NCT00506311
Evaluating the Use of Fibrin Tissue Adhesive in Melanoma Patients treatment Not Available completed NCT02990611
Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy No drug interventions Not Available Not Available active_not_recruiting NCT03978611
A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment treatment 1 terminated NCT00068211
Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma No drug interventions treatment 2 completed NCT04566393
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies Not Available Not Available available NCT02427893
Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma treatment 3 withdrawn NCT05289193
CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma treatment 2 recruiting NCT01502293
Trial of pIL-12 Electroporation Malignant Melanoma treatment 2 completed NCT03709771
Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease No drug interventions Not Available Not Available terminated NCT02407171
Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC treatment 1 / 2 completed NCT05714371
Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma Not Available Not Available completed NCT01546571
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients treatment 3 terminated NCT01829971
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection No drug interventions treatment 1 terminated NCT05768178
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. treatment 2 / 3 recruiting NCT05097378
Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma treatment 2 unknown_status NCT04483778
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults treatment 1 active_not_recruiting NCT01896778
Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer No drug interventions basic_science Not Available completed NCT02327078
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) treatment 1 / 2 completed NCT03915678
Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors treatment 2 recruiting NCT01495988
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma treatment 2 terminated NCT03711188
A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma treatment 2 completed NCT00809588
Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF) No drug interventions treatment 1 completed NCT03504488
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) treatment 1 / 2 recruiting NCT05419388
A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma treatment 2 recruiting NCT03517488
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors treatment 1 completed NCT06212388
Allogeneic Gammadelta T Cells Combined With Interferon-α1b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma treatment 0 not_yet_recruiting NCT02854488
Yervoy Pregnancy Surveillance Study Not Available Not Available withdrawn NCT02724488
Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies No drug interventions Not Available Not Available active_not_recruiting NCT02451488
Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma treatment 4 completed NCT04758988
AI Augmented Training for Skin Specialists No drug interventions diagnostic Not Available enrolling_by_invitation NCT02387307
A Study of rSIFN-co in Subjects With Advanced Solid Tumors treatment 1 completed NCT00342407
The Incidence of Breast and Other Cancers Among Female Flight Attendants No drug interventions Not Available Not Available completed NCT02434107
Complete Lymph Node Dissection vs Watchful Waiting in Patients With Malignant Melanoma (Thickness of 1,0mm+ and Evidence of Metastases in the Sentinel Node) No drug interventions treatment Not Available completed NCT05868707
OH2 Injection in Melanoma No drug interventions treatment 3 recruiting NCT00094107
Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma treatment 2 completed NCT00815607
Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma treatment 1 completed NCT02061007
Biomarker Correlates of Hypoxia in Metastatic Melanoma diagnostic 2 withdrawn NCT03946007
Quality of Life and Physical Fitness After Immune Checkpoint Inhibitors No drug interventions Not Available Not Available completed NCT04357509
The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma No drug interventions treatment 1 unknown_status NCT01764009
Safety and Efficacy of Intramuscular Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma No drug interventions treatment 1 / 2 withdrawn NCT03165409
Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread Not Available Not Available completed NCT03702309
Liquid Biopsy Evaluation and Repository Development at Princess Margaret No drug interventions Not Available Not Available recruiting NCT00613509
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma treatment 2 terminated NCT05027009
Effects of Simulated Solar Radiation on Human Skin in Preventing Skin Cancer No drug interventions basic_science Not Available completed NCT00739609
IDO Inhibitor Study for Relapsed or Refractory Solid Tumors treatment 1 terminated NCT02861209
Collaborative Network to Take Responsibility for Oral Anticancer Therapy No drug interventions supportive_care Not Available unknown_status NCT06463509
Establishment and Standardization of a Platform for In-depth Tumour Profiling (TUPRO) in Patients With Melanoma No drug interventions Not Available Not Available completed NCT03944356
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients Not Available Not Available unknown_status NCT02696356
Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma No drug interventions treatment 1 completed NCT02602756
Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal Melanomas No drug interventions treatment Not Available terminated NCT00625456
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors treatment 1 completed NCT05756556
T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma treatment 2 suspended NCT05075356
iToBoS: Clinical Data Acquisition Study No drug interventions prevention Not Available not_yet_recruiting NCT02035956
IVAC MUTANOME Phase I Clinical Trial No drug interventions treatment 1 completed NCT01245556
Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma treatment 1 completed NCT04979585
Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma treatment 2 unknown_status NCT01336985
Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads treatment 1 terminated NCT03176485
Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors No drug interventions prevention Not Available completed NCT04913285
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors treatment 1 recruiting NCT02400385
A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma treatment 2 withdrawn NCT05668585
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors treatment 1 / 2 recruiting NCT03033485
18F-Labeled Picolinamide PET Imaging of Melanoma Diagnosis No drug interventions diagnostic Not Available unknown_status NCT02621515
Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases diagnostic 2 terminated NCT00710515
Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies treatment 1 completed NCT05156515
PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor No drug interventions diagnostic Not Available recruiting NCT02492815
PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma No drug interventions Not Available Not Available completed NCT04644315
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors treatment 2 terminated NCT01045915
Safety and Efficacy Study of Electrotransfer of Plasmid AMEP to Treat Advanced or Metastatic Melanoma No drug interventions treatment 1 terminated NCT05621837
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy No drug interventions Not Available Not Available unknown_status NCT03394937
Safety of Intranodal ECI-006 in Melanoma Patients No drug interventions treatment 1 terminated NCT00658437
CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy treatment 2 completed NCT05983237
Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma treatment 1 / 2 not_yet_recruiting NCT05061537
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors treatment 1 terminated NCT05169437
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors treatment 2 active_not_recruiting NCT04913337
Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies treatment 1 / 2 active_not_recruiting NCT00365937
Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides treatment 1 / 2 terminated NCT01565837
Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma treatment 2 unknown_status NCT04570332
BO-112 With Pembrolizumab in Unresectable Malignant Melanoma treatment 2 active_not_recruiting NCT00189332
Use of 852A in Metastatic Cutaneous Melanoma. No drug interventions treatment 2 completed NCT01118832
Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi No drug interventions Not Available Not Available completed NCT05723432
KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma treatment 1 / 2 recruiting NCT04385732
Melanoma Surveillance Photography (MSP) to Improve Early Detection of Melanoma in Ultra-high and High Risk Patients No drug interventions diagnostic Not Available active_not_recruiting NCT02482532
Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma No drug interventions treatment 1 completed NCT00001832
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma treatment 2 completed NCT05222932
Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1 treatment 1 recruiting NCT03464032
A Study of BCD-135 in Patients With Advanced Solid Tumors No drug interventions treatment 1 unknown_status NCT02796352
A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study treatment 2 terminated NCT04196452
A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR) Not Available Not Available active_not_recruiting NCT05863052
Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population No drug interventions Not Available Not Available active_not_recruiting NCT00434252
A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma treatment 2 completed NCT01392352
HYPAZ: Hypertension Induced by Pazopanib basic_science 2 terminated NCT01004952
Measuring Real Time Decision-Making About Ultraviolet Radiation (UVR) Protection No drug interventions Not Available Not Available active_not_recruiting NCT02307500
Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy treatment 2 completed NCT00406900
Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma No drug interventions Not Available Not Available unknown_status NCT02975700
A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma treatment Not Available active_not_recruiting NCT03319459
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors treatment 1 completed NCT03771859
A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed No drug interventions Not Available Not Available active_not_recruiting NCT02872259
BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma treatment 1 / 2 completed NCT01021059
A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer No drug interventions treatment 1 completed NCT01990859
Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients treatment 2 completed NCT00788775
Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma treatment 2 completed NCT00059475
Peptide Vaccination for Patients at High Risk for Recurrent Melanoma treatment 2 completed NCT01677975
The Value of Preoperative Dynamic Lymphscintigraphy and Ultrasoundscanning, Eventually With FNA, for Identification of Malignant Sentinel Node(s) in Patients With Melanoma No drug interventions Not Available Not Available unknown_status NCT02425475
FLuorescence Identification of Melanoma by a Multicenter Based Algorithm (FLIMMA) No drug interventions Not Available Not Available completed NCT02129075
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma treatment 2 completed NCT01336270
Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients No drug interventions Not Available Not Available completed NCT02085070
MK-3475 in Melanoma and NSCLC Patients With Brain Metastases treatment 2 completed NCT06163170
A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma Not Available Not Available completed NCT00591370
Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma treatment 2 completed NCT02668770
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies treatment 1 active_not_recruiting NCT01068470
Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy No drug interventions Not Available Not Available terminated NCT03356470
Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma No drug interventions Not Available Not Available completed NCT00683670
Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma treatment 1 completed NCT00188370
Ultrasound Biomicroscopy - Apoptosis No drug interventions diagnostic 2 completed NCT00897442
Collecting Tumor Samples From Patients With Gynecological Tumors No drug interventions Not Available Not Available completed NCT02553642
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) treatment 2 completed NCT04787042
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 treatment 1 / 2 active_not_recruiting NCT05180799
A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody (Currently Enrolling Patients With Nonsquamous or Recurrent NSCLC (Type IIB, IIIA, IV) treatment 1 / 2 recruiting NCT03195699
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers treatment 1 active_not_recruiting NCT03593499
Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401 Not Available Not Available no_longer_available NCT01760499
Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study treatment 1 completed NCT05625399
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma treatment 3 recruiting NCT03772899
Fecal Microbial Transplantation in Combination With Immunotherapy in Melanoma Patients (MIMic) No drug interventions treatment 1 active_not_recruiting NCT02012699
Integrated Cancer Repository for Cancer Research No drug interventions Not Available Not Available recruiting NCT04971499
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma treatment 1 / 2 recruiting NCT02425306
Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma treatment 1 / 2 terminated NCT04436406
PD-L1 Expression in Cancer (PECan Study). No drug interventions diagnostic Not Available recruiting NCT02723006
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma other 1 terminated NCT03340506
Dabrafenib and/or Trametinib Rollover Study treatment 4 recruiting NCT00349206
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma treatment 1 completed NCT00386906
Sentinel Lymph Node (SLN) Biopsy for Conjunctival/Eyelid Melanoma No drug interventions diagnostic 1 active_not_recruiting NCT00847106
Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients treatment 1 / 2 completed NCT05739006
Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies treatment 1 active_not_recruiting NCT04799106
Community Based Strategies for Early Detection of Melanoma No drug interventions Not Available Not Available not_yet_recruiting NCT05115006
A Study of Adjuvant Melanoma Stakeholder Treatment Preferences No drug interventions Not Available Not Available completed NCT03089606
Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker treatment 2 completed NCT02656706
Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma treatment 2 active_not_recruiting NCT02129049
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children No drug interventions supportive_care Not Available completed NCT03552549
SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002) treatment 2 / 3 terminated NCT05817149
Perioperative Examination of Inflammatory Markers in Relation to Sentinel Lymph Node Biopsy in Patients With Melanoma; a Pilot Study No drug interventions Not Available Not Available completed NCT00125749
Vaccination of Patients With Stage IV Melanoma With Dendritic Cells No drug interventions treatment 1 / 2 completed NCT01290536
Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases No drug interventions treatment 2 completed NCT04114136
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies treatment 2 recruiting NCT02668536
A Sunscreen Based on Bioadhesive Nanoparticles No drug interventions prevention 1 completed NCT03553836
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) treatment 3 active_not_recruiting NCT02437136
Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer treatment 1 / 2 completed NCT01183936
Trial of Surgical Excision Margins in Thick Primary Melanoma No drug interventions treatment Not Available completed NCT03301636
A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma treatment 2 terminated NCT04349436
A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies No drug interventions treatment 1 / 2 recruiting NCT03169036
Melanomas Excised in Primary Care vs Secondary Care Excision No drug interventions Not Available Not Available completed NCT05393713
Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study treatment 1 active_not_recruiting NCT03825913
3-month Aerobic and Resistance Exercise Intervention for Individuals Diagnosed With Melanoma No drug interventions supportive_care Not Available terminated NCT02285413
Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients treatment 2 completed NCT06060613
Safety and Efficacy of OBX-115 in Advanced Solid Tumors No drug interventions treatment 1 / 2 recruiting NCT02607813
Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations treatment 1 terminated NCT01543113
cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project No drug interventions diagnostic Not Available completed NCT04234113
Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors treatment 1 active_not_recruiting NCT01682213
Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation treatment 2 completed NCT01121718
NIR-Guided Sentinel Lymph Node Mapping in Melanoma No drug interventions diagnostic 1 completed NCT00912418
Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma No drug interventions treatment Not Available completed NCT04478318
Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma No drug interventions basic_science Not Available enrolling_by_invitation NCT03894618
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas No drug interventions treatment 1 completed NCT01666418
Pilot Study Investigating the Metabolic Activity and Transcriptional Profiling in Vivo in Tumor Biopsies in Melanoma Patients During Treatment With Pazopanib Alone and in Combination With Paclitaxel treatment 2 completed NCT03552718
QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers. No drug interventions treatment 1 active_not_recruiting NCT05223218
Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study No drug interventions Not Available Not Available enrolling_by_invitation NCT05311618
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors treatment 1 active_not_recruiting NCT06090318
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss treatment 1 / 2 withdrawn NCT04726319
Family History App in Personalized Medicine No drug interventions screening Not Available active_not_recruiting NCT01667419
A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma treatment 3 completed NCT00093119
Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma treatment 2 completed NCT02743819
Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma treatment 2 active_not_recruiting NCT06365619
Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma treatment 2 not_yet_recruiting NCT03620019
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma treatment 2 completed NCT03454919
Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations treatment 2 unknown_status NCT04125719
PVSRIPO in Combination With Nivolumab in Melanoma treatment 1 withdrawn NCT01684241
RBL001/RBL002 Phase I Clinical Trial No drug interventions treatment 1 completed NCT01065441
Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer No drug interventions treatment 1 / 2 completed NCT04305041
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) treatment 1 / 2 active_not_recruiting NCT03618641
CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease treatment 2 completed NCT04988841
Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma treatment 2 recruiting NCT02014441
Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec treatment 2 completed NCT02404441
Phase I/II Study of PDR001 in Patients With Advanced Malignancies treatment 1 / 2 completed NCT02869217
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors treatment 1 active_not_recruiting NCT06384417
Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2 No drug interventions supportive_care Not Available recruiting NCT02988817
Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors treatment 1 / 2 completed NCT04091217
Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma treatment 2 completed NCT01658917
Collecting Solid Tumor Tissue to Identify New Treatments No drug interventions Not Available Not Available completed NCT04157517
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors other 1 / 2 completed NCT00885534
Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma treatment 2 completed NCT00522834
Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma treatment 3 terminated NCT03554434
An Expanded Access Program for AM0010 (Pegilodecakin) Not Available Not Available no_longer_available NCT05620134
Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer treatment 1 / 2 recruiting NCT06028724
A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN) No drug interventions Not Available Not Available recruiting NCT00590824
Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma treatment 2 completed NCT04025424
Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519) No drug interventions Not Available Not Available unknown_status NCT02830724
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers treatment 1 / 2 recruiting NCT03809624
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer treatment 1 active_not_recruiting NCT02854124
Tracing Dissemination of Melanoma Cells in Healthy Tissues No drug interventions Not Available Not Available completed NCT00112216
Immunotherapy of Melanoma Patients No drug interventions treatment 1 completed NCT06246916
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma treatment 3 recruiting NCT00289016
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma treatment 2 completed NCT02014116
A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body No drug interventions treatment 1 terminated NCT00057616
Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma. prevention 3 completed NCT04348916
Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors treatment 1 terminated NCT02583516
Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma treatment 2 completed NCT04576416
Artificial Intelligence Augmented Training in Skin Cancer Diagnostics for General Practitioners No drug interventions diagnostic Not Available completed NCT03729596
MGC018 With or Without MGA012 in Advanced Solid Tumors treatment 1 / 2 terminated NCT01034696
Pain Prevalence and Risk Factors Among Sarcoma/Melanoma Oncology Patients in an Outpatients Setting No drug interventions Not Available Not Available completed NCT01085396
Use of Fiber-optic Probe for Non-invasive Diagnosis of Melanoma and Assessment of Impact of Ultraviolet (UV) Exposure on Skin No drug interventions Not Available Not Available terminated NCT00418496
Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma treatment 1 completed NCT03957096
A Safety Study of SGN-CD47M in Patients With Solid Tumors No drug interventions treatment 1 terminated NCT00001296
A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma treatment 3 completed NCT00970996
Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma treatment 1 completed NCT00066196
Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma treatment 2 completed NCT01568996
Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor Lesions prevention 0 completed NCT04751396
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors No drug interventions Not Available Not Available recruiting NCT06254196
Clinical Trial of Telenursing for Monitoring Supportive Care Needs in Patients With Lung Cancer and Melanoma Candidates for the First Prescription of Targeted Therapies No drug interventions supportive_care Not Available recruiting NCT02619058
A Clinical Trial of Adoptive Transfer With Autologous NKT Cells in Metastatic Melanoma Patients No drug interventions treatment 1 unknown_status NCT04208958
Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer treatment 1 / 2 completed NCT01970358
A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma prevention 1 completed NCT03896958
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology) No drug interventions Not Available Not Available unknown_status NCT04206358
Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From Melanoma treatment 1 unknown_status NCT05063058
Biomarker-driven Therapy for Melanoma No drug interventions basic_science Not Available completed NCT03412058
Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists No drug interventions other Not Available active_not_recruiting NCT02628535
Safety Study of MGD009 in B7-H3-expressing Tumors No drug interventions treatment 1 terminated NCT02300935
Study of Trametinib and Nab-paclitaxel in Patients With Melanoma treatment 1 withdrawn NCT00505635
Biochemotherapy With Temozolomide for Metastatic Melanoma treatment 2 terminated NCT05573035
A Study to Investigate LYL845 in Adults With Solid Tumors No drug interventions treatment 1 recruiting NCT01294735
Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1) treatment 1 completed NCT02700763
[18F]Dabrafenib Molecular Imaging in Melanoma Brain Metastasis No drug interventions other Not Available terminated NCT01153763
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma treatment 2 completed NCT02107963
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors treatment 1 completed NCT00027586
Imatinib Mesylate in Treating Patients With Metastatic Melanoma treatment 2 completed NCT05707286
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy No drug interventions Not Available Not Available recruiting NCT02115139
GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases treatment 2 completed NCT00001439
A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant No drug interventions treatment 1 completed NCT03374839
Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients treatment 1 / 2 unknown_status NCT04629339
Study of INCB086550 in Select Solid Tumors treatment 2 terminated NCT05907122
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma treatment 3 recruiting NCT03205722
The Effectiveness of Nivolumab Monotherapy as First-Line Therapy in Adults With Advanced Melanoma in Germany No drug interventions Not Available Not Available withdrawn NCT01943422
Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma treatment 1 completed NCT03132922
MAGE-A4ᶜ¹º³²T for Multi-Tumor No drug interventions treatment 1 active_not_recruiting NCT03165422
A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan No drug interventions Not Available Not Available completed NCT04570722
Ipsilateral Peripheral Intravenous Access Procedures (The iPIVAP Study) No drug interventions other Not Available completed NCT05432622
A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy No drug interventions Not Available Not Available completed NCT01281722
Role of SLURP-1 in Melanoma and Melanoma Stem Cells No drug interventions Not Available Not Available unknown_status NCT01028222
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation prevention 2 completed NCT04762225
RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma No drug interventions treatment 1 terminated NCT02387125
Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 treatment 1 terminated NCT02613325
fPAM for the in Vivo Depth Measurement of Pigmented Lesions and Melanoma Depth No drug interventions diagnostic 1 completed NCT05148325
Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT4706 in Advanced Solid Tumors No drug interventions treatment 1 recruiting NCT03784625
Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012 No drug interventions treatment 0 recruiting NCT00412425
Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting treatment 1 / 2 completed NCT04001725
Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Patients With Brain Metastases prevention 2 unknown_status NCT03259425
Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma treatment 2 terminated NCT02562625
Trial of Pembrolizumab and Radiotherapy in Melanoma treatment 2 terminated NCT00338130
Randomised Study to Compare the Efficacy of AZD6244 vs TMZ treatment 2 completed NCT00912730
A Pilot Study of Intraoperative Gamma Camera Imaging During Sentinel Node Biopsy for Melanoma No drug interventions Not Available Not Available completed NCT05877430
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer treatment 1 / 2 recruiting NCT04986748
Using QPOP to Predict Treatment for Sarcomas and Melanomas No drug interventions Not Available Not Available recruiting NCT04544748
A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies No drug interventions treatment 1 active_not_recruiting NCT02836548
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma treatment 1 / 2 unknown_status NCT01584648
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma treatment 3 completed NCT02900248
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice No drug interventions Not Available Not Available terminated NCT03399448
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) other 1 terminated NCT01752257
EF5 in Melanoma Patients No drug interventions diagnostic 1 completed NCT00527657
Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients treatment 1 completed NCT00434057
Evaluation of Pigmented Skin Lesions With MelaFind(R) System No drug interventions diagnostic 3 completed NCT02854657
Teaching Skin Self -Examination to Melanoma Patients and Their Skin Check Partners No drug interventions prevention Not Available completed NCT01986426
LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab treatment 1 completed NCT04663126
Feasibility of IV Tc-99m-tilmanocept for Imaging of M2-like TAMs in Metastatic Melanoma other 0 terminated NCT02771626
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) treatment 1 / 2 terminated NCT01781026
Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases treatment 2 completed NCT03627026
Evaluation of Sphingolipids as Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Melanoma Patients No drug interventions other Not Available completed NCT06424626
A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma treatment 1 not_yet_recruiting NCT00828126
PET-CT in the Management of Patients With Stage III or IV Metastatic Melanoma No drug interventions Not Available Not Available completed NCT02639026
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers treatment 1 completed NCT04609566
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors treatment 2 recruiting NCT04198766
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) treatment 1 / 2 recruiting NCT03253666
Nurses' Health Study and Health Professionals Follow-Up Study (Dermatological Component) No drug interventions Not Available Not Available completed NCT02905266
A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma treatment 3 completed NCT05429866
Immunological Variables Associated to ICI Toxicity in Cancer Patients other 2 recruiting NCT00901966
Sun Exposure and Melanoma in Agricultural Workers No drug interventions Not Available Not Available completed NCT02130466
A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) treatment 1 / 2 completed NCT02718066
Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer treatment 1 / 2 completed NCT05406466
Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis treatment 2 recruiting NCT02915666
A Clinical Trial of Patients With Melanoma treatment 1 withdrawn NCT00623766
Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases treatment 2 completed NCT00257465
Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma treatment 1 / 2 completed NCT05899465
Perioperative Treatment With Tranexamic Acid in Melanoma prevention 3 recruiting NCT02897765
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer treatment 1 completed NCT00035165
EPO906 Therapy in Patients With Advanced Melanoma treatment 2 completed NCT03269565
International Trial of the Efficacy and Safety of BCD-100 in Patients With Melanoma No drug interventions treatment 2 unknown_status NCT00803374
Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma treatment 1 withdrawn NCT02752074
A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301) treatment 3 completed NCT04546074
Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma treatment 1 / 2 recruiting NCT05859074
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer treatment 1 active_not_recruiting NCT04180774
Safety and Efficacy of Tag-7 Gene-modified Vaccine in Locally Advanced or Metastatic Malignant Melanoma or Kidney Cancer No drug interventions treatment 1 / 2 completed NCT03190174
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers treatment 1 / 2 completed NCT05275374
XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation treatment 1 / 2 not_yet_recruiting NCT01409174
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma treatment 1 terminated NCT03997474
ATL001 in Patients With Metastatic or Recurrent Melanoma No drug interventions treatment 1 / 2 recruiting NCT05215574
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors treatment 1 recruiting NCT01619774
An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor treatment 2 completed NCT06081920
A Study of IBI363 in Subjects With Advanced Melanoma No drug interventions treatment 2 recruiting NCT05578820
Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid treatment 1 completed NCT04234620
Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) . Not Available Not Available unknown_status NCT01590082
Doxycycline, Temozolomide and Ipilimumab in Melanoma treatment 1 / 2 terminated NCT01636882
CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext) treatment 2 completed NCT03580382
Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma treatment 1 / 2 terminated NCT02821182
A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma. No drug interventions treatment 2 completed NCT00002882
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma treatment 3 completed NCT04337931
A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma treatment 2 terminated NCT00028431
Novel Adjuvants for Peptide-Based Melanoma Vaccines treatment 1 completed NCT04631731
Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity No drug interventions diagnostic 1 / 2 recruiting NCT06332131
Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature No drug interventions Not Available Not Available not_yet_recruiting NCT02259231
RTA 408 Capsules in Patients With Melanoma - REVEAL treatment 1 / 2 completed NCT00525031
Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients treatment 2 completed NCT01946373
T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma treatment 1 recruiting NCT02917473
Comparison of Two Strategies for Counseling Skin Examination and Sun Protection in First-degree Relatives of Patients With Melanoma No drug interventions screening Not Available completed NCT04834973
A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma treatment 1 / 2 terminated NCT05570227
Metabolic Phenotypes in Melanoma No drug interventions basic_science Not Available recruiting NCT04205227
ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors treatment 1 / 2 active_not_recruiting NCT05819827
Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics No drug interventions Not Available Not Available recruiting NCT01008527
Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100 treatment 1 completed NCT02516527
A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors basic_science 1 completed NCT01941927
Trametinib With GSK2141795 in BRAF Wild-type Melanoma treatment 2 completed NCT06246227
ctDNA for Early Detection of Recurrence in Melanoma No drug interventions Not Available Not Available active_not_recruiting NCT01840527
Utility of Novel BRAF Test for Melanoma No drug interventions Not Available Not Available completed NCT03934827
MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour treatment 1 unknown_status NCT00289627
A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma treatment 2 completed NCT04802876
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors treatment 2 recruiting NCT04860076
Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors Not Available Not Available unknown_status NCT03450876
Long Term Quality of Life in Melanoma Patients in Netherlands No drug interventions Not Available Not Available completed NCT01209676
IMCgp100 in Advanced Unresectable Melanoma treatment 0 completed NCT01638676
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients treatment 1 / 2 recruiting NCT02335476
Automatic Early Melanoma Detection by Ultrahigh Resolution Three Dimensional Optical Coherence Tomography No drug interventions Not Available Not Available unknown_status NCT05744076
Analysis of Circulating Exosomes in Melanoma Patients No drug interventions Not Available Not Available active_not_recruiting NCT03088176
Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma treatment 1 unknown_status NCT03732560
A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US No drug interventions Not Available Not Available completed NCT05522660
Immunotherapy or Targeted Therapy with or Without Stereotactic Radiosurgery for Patients with Brain Metastases from Melanoma or Non-small Cell Lung Cancer No drug interventions treatment 3 recruiting NCT01432860
A Comparison of Interventions to Teach Melanoma Patients Skin Self-examination No drug interventions screening Not Available completed NCT03098160
Immunotherapy Study of Evofosfamide in Combination With Ipilimumab treatment 1 unknown_status NCT00615160
PTK/ZK in Disseminated Malignant Melanoma treatment 1 / 2 terminated NCT02574260
An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016) treatment 2 completed NCT00580060
Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity treatment 0 completed NCT00110994
Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma treatment 2 completed NCT01573494
Study of Circulating Tumor Cells Before and After Treatment in Patients With Metastatic Melanoma No drug interventions diagnostic Not Available completed NCT01127594
Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion treatment 1 completed NCT01608594
Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma treatment 1 completed NCT02839694
Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy treatment 1 withdrawn NCT05031494
A Study to Assess YH003 in Combination With Toripalimab(Anti-PD-1 mAb) Injection in Patients With Cancers treatment 2 active_not_recruiting NCT06500091
TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors treatment 2 not_yet_recruiting NCT03685591
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors treatment 1 terminated NCT05103891
Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations other 1 unknown_status NCT05029791
Variations of Immune Infiltrate and Cell Plasticity Markers in Treated Metastatic Melanoma Patients No drug interventions other Not Available recruiting NCT03511391
CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors treatment 2 completed NCT06204991
To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma treatment 1 not_yet_recruiting NCT04657991
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma treatment 3 active_not_recruiting NCT06363591
Single- vs Two-staged Excisions of Thin Melanoma No drug interventions treatment Not Available not_yet_recruiting NCT02088762
Impact of Excision Margins on Survival and Recurrence Rate in Patients With Thick Melanoma (>2mm) No drug interventions Not Available Not Available completed NCT00942162
A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma treatment 2 completed NCT00745862
Illness Related Distress in Women With Clinically Localized Cutaneous Melanoma No drug interventions Not Available Not Available completed NCT01709162
Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma treatment 2 terminated NCT05208762
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors treatment 1 recruiting NCT00441662
Sub-Tenon Triamcinolone in the Prevention of Radiation-Induced Macular Edema prevention Not Available completed NCT05054062
Sentinel Lymph Node Mapping Using Magtrace and MRI in Healthy Subjects for Potential Use in Melanoma Patients No drug interventions diagnostic Not Available completed NCT03354962
Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) treatment 1 / 2 terminated NCT01308762
A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients Not Available 1 completed NCT02968680
Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma diagnostic 1 terminated NCT04866680
Personalized Circulating DNA Follow-up in Melanoma (PERCIMEL) No drug interventions diagnostic Not Available recruiting NCT03758729
Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma. treatment 2 withdrawn NCT06194929
Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma treatment 1 / 2 recruiting NCT01960829
Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study treatment 2 unknown_status NCT03929029
Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma treatment 1 active_not_recruiting NCT01313429
Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum treatment 1 terminated NCT03765229
An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma treatment 2 completed NCT06415929
Etude rétrospective Monocentrique MATRIX No drug interventions Not Available Not Available completed NCT05145829
Exploring an Alternative Pre-operative SLN Mapping Method Using a Magnetic Tracer and MRI for Melanoma Patients No drug interventions diagnostic Not Available recruiting NCT00204529
Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB treatment 3 completed NCT04772989
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies treatment 1 active_not_recruiting NCT03757689
Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C Melanoma treatment 2 active_not_recruiting NCT01753089
Dendritic Cell Activating Scaffold in Melanoma No drug interventions treatment 1 active_not_recruiting NCT05827289
'Cancer Patients Better Life Experience' No drug interventions screening Not Available recruiting NCT06548789
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED No drug interventions supportive_care 2 not_yet_recruiting NCT00610389
Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors No drug interventions treatment 2 unknown_status NCT00824889
Exploratory Study of Natural Killer Cells in Human Skin No drug interventions Not Available Not Available completed NCT00706992
Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients treatment 2 terminated NCT05496192
A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer treatment 2 withdrawn NCT00160992
Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed Melanoma Patients No drug interventions treatment 1 suspended NCT00463892
High-resolution Magnetic Resonance Imaging (MRI) Scans to Look for Spread of Melanoma to Nearby Lymph Nodes No drug interventions diagnostic 2 completed NCT02138292
A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma treatment 1 completed NCT01984892
Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC) treatment 2 terminated NCT02967692
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma treatment 3 active_not_recruiting NCT00574392
Multi-Wavelength and Coherence Confocal Reflectance Microscopy of Pigmented and Non-Pigmented Lesions on the Skin In-Vivo No drug interventions Not Available Not Available completed NCT05770544
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. treatment 2 / 3 recruiting NCT03313544
Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1 diagnostic 4 recruiting NCT01931644
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions No drug interventions Not Available Not Available completed NCT05270044
Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. treatment 3 active_not_recruiting NCT05912244
A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma treatment 2 recruiting NCT03747744
Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC) No drug interventions treatment 1 unknown_status NCT03754140
Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases treatment 2 withdrawn NCT01106040
Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes diagnostic 3 completed NCT05061940
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols. No drug interventions Not Available Not Available terminated NCT06321640
Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies. No drug interventions Not Available Not Available recruiting NCT03435640
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies treatment 1 / 2 terminated NCT00289640
Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma treatment 2 completed NCT03407040
Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy No drug interventions Not Available Not Available terminated NCT05810740
Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations other 1 completed NCT06229340
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations basic_science 2 recruiting NCT06521567
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer treatment 1 / 2 not_yet_recruiting NCT02986867
SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma No drug interventions basic_science Not Available completed NCT04498767
Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE) No drug interventions treatment Not Available recruiting NCT04169867
Polish Microbiome Map Not Available Not Available unknown_status NCT03207867
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma treatment 2 terminated NCT00700167
Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy No drug interventions treatment 1 completed NCT04074967
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab treatment 1 / 2 active_not_recruiting NCT04106167
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy No drug interventions Not Available Not Available terminated NCT04474301
Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic No drug interventions Not Available Not Available recruiting NCT03111901
Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer treatment 1 / 2 withdrawn NCT05229601
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors No drug interventions treatment 1 active_not_recruiting NCT05740501
Pharmacokinetic Profiling of Pembrolizumab and Nivolumab in Patients With Melanoma and/or Non-Small Cell Lung Cancer No drug interventions Not Available Not Available completed NCT01350401
Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma No drug interventions treatment 1 / 2 terminated NCT03212404
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers treatment 1 recruiting NCT02054104
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum treatment 1 / 2 terminated NCT05727904
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. treatment 3 recruiting NCT04032704
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors treatment 2 terminated NCT02156804
A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172) treatment 2 completed NCT01500304
Minimally Invasive Groin Dissection for Melanoma No drug interventions treatment Not Available completed NCT02527304
Adaptive Staged Stereotactic Body Radiation Therapy in Treating Patients With Spinal Metastases That Cannot Be Removed by Surgery No drug interventions treatment Not Available completed NCT01456104
Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma No drug interventions treatment 1 completed NCT02978404
Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases treatment 2 completed NCT06566404
Gene Expression Profiles and ctDNA for Risk Stratification in Patients With Melanoma No drug interventions Not Available Not Available not_yet_recruiting NCT02431572
A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy No drug interventions diagnostic Not Available completed NCT02908672
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma treatment 3 active_not_recruiting NCT04039672
Interest of Tumor Replicates in Avian Embryo to Model Therapeutic Effects of BRAFi/MEKi in BRAF Mutated Melanoma No drug interventions diagnostic Not Available recruiting NCT05352672
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma treatment 3 recruiting NCT03979872
Risk Information and Skin-cancer Education for Undergraduate Prevention No drug interventions prevention Not Available completed NCT04666272
Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection Not Available Not Available recruiting NCT00597272
Determine Toxicity and Antibody Responses With a KLH Conjugated Bivalent Vaccine Containing GD2 Lactone, GD3 Lactone With Immunological Adjuvant QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV Cutaneous Melanoma No drug interventions treatment Not Available completed NCT01213472
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma No drug interventions treatment 1 completed NCT04720768
Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE treatment 1 / 2 recruiting NCT03501368
Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma treatment 1 active_not_recruiting NCT02482168
Study of the CD40 Agonistic Monoclonal Antibody APX005M treatment 1 completed NCT04611568
War on Melanoma™ Public Health & Education Campaign No drug interventions prevention Not Available recruiting NCT04268368
Immune Related-adverse Events in Patients Receiving Immune Checkpoint Inhibitors No drug interventions Not Available Not Available unknown_status NCT05789069
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors treatment 1 recruiting NCT05002569
A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma treatment 3 active_not_recruiting NCT02069769
Ensuring Communication in Hospice by Oncology Study (ECHO) No drug interventions supportive_care Not Available completed NCT06362369
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy treatment 1 / 2 recruiting NCT05334069
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection No drug interventions Not Available Not Available recruiting NCT02600169
Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab Not Available Not Available completed NCT03849469
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors treatment 1 completed NCT04303169
Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) treatment 1 / 2 active_not_recruiting NCT04605146
Impact of Telemonitoring for the Management of Side Effects in Patients With Melanoma, Lung or Renal Cancer, Treated With Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy No drug interventions supportive_care Not Available recruiting NCT05823246
Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma No drug interventions treatment 2 recruiting NCT01882946
Safety and Efficacy Study of DCVax-Direct in Solid Tumors No drug interventions treatment 1 / 2 unknown_status NCT04250246
A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 treatment 2 not_yet_recruiting NCT00111046
Pain Relief - Tramadol Versus Ibuprofen treatment 1 / 2 unknown_status NCT03199846
Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States No drug interventions Not Available Not Available completed NCT00246012
A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma treatment 1 / 2 completed NCT04495010
Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants treatment 2 withdrawn NCT02032810
Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma treatment 1 completed NCT03841110
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors treatment 1 completed NCT04866810
The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN) No drug interventions other Not Available recruiting NCT03267381
Circulating Blood Profile to Predict Recurrence and Response to Systemic Therapy No drug interventions Not Available Not Available completed NCT06237881
A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors treatment 1 / 2 recruiting NCT03428581
Preventing Lymphedema in Axillary Lymph Node Dissection No drug interventions prevention Not Available active_not_recruiting NCT05512481
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma treatment 2 recruiting NCT01557881
Positron Emission Tomography/Magnetic Resonance Imaging in Patients No drug interventions diagnostic Not Available terminated NCT01888081
A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma treatment 1 / 2 terminated NCT00204581
Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases treatment 2 completed NCT00412581
Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma treatment 1 completed NCT00923195
Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma treatment 2 completed NCT02316795
Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma No drug interventions diagnostic 0 completed NCT05607095
Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma treatment 1 recruiting NCT05909995
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors treatment 1 active_not_recruiting NCT00518895
Trial of Dacarbazine With or Without Genasense in Advanced Melanoma treatment 3 completed NCT05527795
Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected Melanoma No drug interventions Not Available Not Available recruiting NCT05665595
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) treatment 3 active_not_recruiting NCT04401995
Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab treatment 2 active_not_recruiting NCT00826995
Comparison of Video-Based Versus Written Patient Education on Melanoma No drug interventions Not Available Not Available completed NCT02846714
Family Lifestyle Actions and Risk Education Study No drug interventions prevention Not Available completed NCT01700114
Post-Approval Study of MelaFind No drug interventions Not Available Not Available terminated NCT01813214
The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma treatment 2 terminated NCT03068455
An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma treatment 3 completed NCT05053555
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies No drug interventions treatment Not Available recruiting NCT03329755
Optimization of the Patient Care Pathway in Immuno-oncology No drug interventions health_services_research Not Available completed NCT03804255
Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting No drug interventions Not Available Not Available withdrawn NCT05819255
TRAQinform Assessment of Immunotherapy Response No drug interventions Not Available Not Available recruiting NCT02110355
A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma treatment 1 completed NCT04289155
Individual Patient Compassionate Use of GX-I7 No drug interventions Not Available Not Available no_longer_available NCT01650350
Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer treatment 2 terminated NCT03329950
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies treatment 1 completed NCT04353050
Atypical MOLes and Melanoma Early Detection Study (MoleMed) No drug interventions diagnostic Not Available unknown_status NCT02306850
Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma treatment 2 completed NCT03989050
Immunogenicity and Safety of Pneumococcal Vaccination in Patients Treated With Immune Checkpoint Inhibitors No drug interventions Not Available Not Available withdrawn NCT00147550
MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma. treatment 1 / 2 terminated NCT05373823
MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors No drug interventions screening Not Available recruiting NCT00938223
Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma No drug interventions treatment 2 completed NCT02352623
Quality of Life and Surgical Late Effects of Melanoma Treatment No drug interventions Not Available Not Available completed NCT03834623
Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma treatment 2 completed NCT00162123
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies treatment 2 completed NCT04201223
Family Lifestyles, Actions, and Risk Education Intervention: Version 2 No drug interventions prevention Not Available active_not_recruiting NCT06239623
ERK Inhibitor JSI-1187 in Advanced Solid Tumors No drug interventions treatment 1 recruiting NCT03007823
High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma No drug interventions treatment 1 / 2 completed NCT02818023
Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma treatment 1 terminated NCT04899908
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases treatment 2 recruiting NCT03224208
Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients treatment 2 terminated NCT02101008
Disulfiram and Chelated Zinc for the Rx of Disseminated Mets Mel That Has Failed First Line Therapy treatment 2 completed NCT01425008
Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma treatment 1 completed NCT01851408
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma treatment 2 withdrawn NCT00041808
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver treatment 1 / 2 completed NCT05429138
Ovarian Reserve and Semen Parameters Evolution During Adjuvant Therapy in Melanoma No drug interventions Not Available Not Available recruiting NCT03362138
Artificial Intelligence-assisted Evaluation of Pigmented Skin Lesions No drug interventions Not Available Not Available unknown_status NCT00706238
MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma treatment 2 terminated NCT04096638
Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors treatment 1 active_not_recruiting NCT06580938
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer treatment 1 not_yet_recruiting NCT02159443
Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody No drug interventions Not Available Not Available completed NCT01391143
Safety Study of MGA271 in Refractory Cancer treatment 1 completed NCT01149343
Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer No drug interventions treatment 1 completed NCT06240143
Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma treatment 1 / 2 not_yet_recruiting NCT05340543
Ex-vivo Examination of Excisions of Skin Tumors by Confocal Optical Coherence Tomography (LC-OCT) With Integrated Dermoscopy and Comparison With Histology (DERMOCTAV) No drug interventions Not Available Not Available unknown_status NCT02314143
Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib diagnostic 2 terminated NCT03300843
Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer No drug interventions treatment 2 terminated NCT02819843
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors treatment 2 completed NCT04729543
MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer treatment 1 / 2 recruiting NCT00001503
Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease No drug interventions Not Available Not Available completed NCT01586403
Transfer of Genetically Engineered Lymphocytes in Melanoma Patients No drug interventions treatment 1 active_not_recruiting NCT03637803
Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors treatment 1 / 2 terminated NCT01962103
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors treatment 1 / 2 completed NCT01351103
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands treatment 1 active_not_recruiting NCT05212103
PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9 No drug interventions Not Available Not Available enrolling_by_invitation NCT05867303
A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors No drug interventions treatment 1 active_not_recruiting NCT05620290
MRI-Guided Focused Ultrasound Radiosensitization for Patients With Malignant Melanoma and Non Melanoma Skin Cancer treatment 1 recruiting NCT00769990
Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases No drug interventions treatment 1 / 2 withdrawn NCT03685890
Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion treatment 1 / 2 recruiting NCT02658890
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread treatment 1 / 2 completed NCT00587964
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases No drug interventions treatment 2 completed NCT00963664
Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma treatment 2 withdrawn NCT02203864
Dose Escalation Study to Evaluate Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 in Patients With Advanced Malignant Melanoma No drug interventions treatment 1 completed NCT04435964
Gender Difference in sidE eFfects of ImmuNotherapy: a Possible Clue to Optimize cancEr tReatment No drug interventions Not Available Not Available completed NCT05878964
Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors. No drug interventions Not Available Not Available recruiting NCT02717364
Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma No drug interventions Not Available Not Available completed NCT06272864
BostonGene and Exigent Genomic INsight Study No drug interventions Not Available Not Available recruiting NCT03272464
INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors. treatment 1 terminated NCT00844064
Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2 treatment 1 completed NCT03171064
Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment No drug interventions supportive_care 2 completed NCT02557321
PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma treatment 1 / 2 active_not_recruiting NCT05302921
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors treatment 2 active_not_recruiting NCT05709821
IMM60 and Pembrolizumab in Melanoma and NSCLC treatment 1 / 2 terminated NCT04899921
Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets treatment 2 terminated NCT02858921
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma treatment 2 active_not_recruiting NCT05770102
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition treatment 2 / 3 recruiting NCT00185302
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma treatment 2 completed NCT05068102
A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab treatment 1 recruiting NCT05354102
A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 treatment 1 active_not_recruiting NCT01770002
Eversion in Dermatologic Surgery: Is Cosmetic Appearance Improved? No drug interventions supportive_care Not Available completed NCT05900102
EVALUATING THE CURRENT STANDARD OF CARE FOR PATIENTS DIAGNOSED WITH MALIGNANT MELANOMA OF THE HEAD AND NECK - ACCESS TO STAGING AND SURGICAL TREATMENT No drug interventions Not Available Not Available not_yet_recruiting NCT05116202
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) treatment 1 / 2 completed NCT03435302
HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma treatment 3 unknown_status NCT02599402
Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma treatment 3 completed NCT01433302
Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass No drug interventions Not Available Not Available completed NCT04544202
Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection Not Available Not Available available NCT03293784
TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma treatment 1 completed NCT01711684
Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP) treatment 1 completed NCT00749684
Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083) Not Available Not Available completed NCT05260684
Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US Not Available Not Available completed NCT02126579
Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists No drug interventions treatment 1 / 2 completed NCT03438279
Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy No drug interventions Not Available Not Available completed NCT01449279
Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy treatment 2 completed NCT03095079
Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma treatment 2 unknown_status NCT03937024
GEN1042 Safety Trial in Subjects With Malignant Solid Tumors No drug interventions treatment 1 / 2 not_yet_recruiting NCT01867619
Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients treatment 2 withdrawn NCT02605473
Parallel Trial of Decitabine and Peg-Interferon in Melanoma: Phase II Portion treatment 2 withdrawn NCT06320353
Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma treatment 3 active_not_recruiting NCT03716193
Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron Paramagnetic Resonance (EPR) Oximetry No drug interventions other Not Available recruiting NCT06307093
Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms treatment 1 active_not_recruiting NCT02417948
Improving Sun-Protective Behaviors and Skin Self-Examinations Among African Americans No drug interventions prevention Not Available completed NCT04734704
Defining the Role of the Skin Microbiome in Immune-related Adverse Events No drug interventions diagnostic Not Available unknown_status NCT03543969
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma treatment 0 recruiting NCT05990634
LifeChamps Feasibility Study No drug interventions supportive_care Not Available active_not_recruiting NCT05982600
Safety and Avoidance of Futile Excisions Through Skin Tele-triage No drug interventions Not Available Not Available enrolling_by_invitation NCT05940311
Versatile Ampification Single-Molecule Detection in Liquid Biopsy No drug interventions Not Available Not Available recruiting NCT05315258
Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma diagnostic 2 recruiting NCT05015816
MoleGazer Development Feasibility Study No drug interventions other Not Available active_not_recruiting NCT04969419
Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo No drug interventions Not Available Not Available completed NCT04911998
A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients No drug interventions Not Available Not Available recruiting NCT04821570
To Assess Immunogenicity of Coronavirus Disease 2019 (COVID-19) Vaccine in Cancer Patients Receiving Cancer Treatment No drug interventions Not Available Not Available active_not_recruiting NCT04605822
Melanoma Detection in Switzerland With VECTRA No drug interventions Not Available Not Available completed NCT04534309
Behavioral Weight Loss Program for Cancer Survivors in Maryland No drug interventions prevention Not Available completed NCT04507048
Passive Versus Active Educational Interventions for Melanoma Recognition No drug interventions other Not Available completed NCT03927742
Wearable Device Intervention to Improve Sun Behaviors in Melanoma Survivors No drug interventions prevention Not Available completed NCT04168528
Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT No drug interventions diagnostic 1 / 2 recruiting NCT04072900
A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma treatment 1 unknown_status NCT03949153
Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis other 1 / 2 completed NCT03893019
MB-CART20.1 Melanoma No drug interventions treatment 0 terminated NCT03535077
Assessing Tissue Remodeling in the Skin Using SFI (Skin Fluorescence Imaging) No drug interventions Not Available Not Available completed NCT04695015
Research of Pathological Imaging Diagnosis of Ocular Tumors Based on New Artificial Intelligence Algorithm No drug interventions Not Available Not Available unknown_status NCT05421988
Effectiveness of Group and Individual Training in EFT for Patients in Remission From Melanoma No drug interventions supportive_care Not Available active_not_recruiting NCT05661370
App Teaches Doctors to Diagnose Skin Cancer No drug interventions other Not Available completed NCT05704647
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases treatment 2 recruiting NCT05906277
Biobanking and New Biomolecular Metrics No drug interventions diagnostic Not Available recruiting NCT06298734
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial No drug interventions supportive_care Not Available recruiting NCT03416933
Therapeutic Drug Monitoring of BRAF-mutated Advanced Melanoma No drug interventions other Not Available completed NCT03311542
Expanded Access for Pembrolizumab (MK-3475) Not Available Not Available no_longer_available NCT05712551
Dermoscopy Augmented Histology Trial, Consensus Agreement Diagnosis Made by Dermatopathology Experts No drug interventions Not Available Not Available enrolling_by_invitation NCT02997553
Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery diagnostic 3 completed NCT02993315
Melanoma Patients Immunized With Natural DenDritic Cells No drug interventions treatment 3 active_not_recruiting NCT01209299
Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate No drug interventions Not Available Not Available completed NCT01176461
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558 treatment 1 completed NCT01005537
Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma Not Available Not Available no_longer_available NCT00962845
Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery treatment 0 completed NCT00898183
S9431: Studying Genes and Immune Response in Tumor Samples From Patients With Locally Advanced or Metastatic Melanoma No drug interventions Not Available Not Available completed NCT00863330
Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma No drug interventions treatment 2 terminated NCT00729807
0794GCC: Pentamidine in Treating Patients With Relapsed or Refractory Melanoma treatment 2 terminated NCT00667641
Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors treatment 1 completed NCT00617799
Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma Not Available Not Available completed NCT00602199
ABT-510 in Treating Patients With Metastatic Melanoma treatment 2 completed NCT00538005
Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma treatment 1 / 2 unknown_status NCT00560118
Fotemustine in Treating Patients With Metastatic Melanoma treatment 2 completed NCT00550654
Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain No drug interventions treatment 2 terminated NCT00514085
Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma treatment 2 completed NCT00471887
Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma treatment 2 completed NCT00471133
Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation treatment 1 completed NCT00471471
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery treatment 1 completed NCT00445783
Study of Families With Melanoma No drug interventions Not Available Not Available unknown_status NCT00447356
High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII Melanoma treatment 3 withdrawn NCT00450593
Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma No drug interventions Not Available Not Available unknown_status NCT00436930
Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma treatment 2 completed NCT00404235
Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery treatment 2 completed NCT00295958
LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery treatment 2 completed NCT00278122
Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery treatment 2 suspended NCT00118313
Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma treatment 1 completed NCT00095953
SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma treatment 2 completed NCT00104988
S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery treatment 2 completed NCT00126685
Vaccine Therapy in Treating Patients With Stage IV Melanoma No drug interventions treatment 1 / 2 unknown_status NCT00104845
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma No drug interventions treatment 1 completed NCT00074230
Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma No drug interventions treatment 1 / 2 completed NCT00077532
Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma treatment 2 completed NCT00072124
Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma treatment 3 completed NCT00081042
ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma treatment 2 completed NCT00085488
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma No drug interventions treatment 1 completed NCT00085059
Boron Neutron Capture Therapy Using Boronophenylalanine-Fructose Complex in Treating Patients With Metastatic Melanoma treatment 2 terminated NCT00059800
Boron Neutron Capture Therapy in Treating Patients With Melanoma No drug interventions treatment 2 completed NCT00033228
Vaccine Therapy in Treating Patients With Stage IV Melanoma No drug interventions treatment 1 / 2 completed NCT00039325
Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma No drug interventions treatment 1 / 2 completed NCT00045149
Biological Therapy in Treating Patients With Metastatic Melanoma treatment 1 completed NCT00037037
Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma treatment 1 unknown_status NCT00042783
Vaccine Therapy in Treating Patients With Stage IV Melanoma No drug interventions treatment 2 completed NCT00019734
Vaccine Therapy in Treating Patients With Metastatic Melanoma treatment 2 completed NCT00031733
Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma treatment 2 completed NCT00032045
Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma treatment 2 completed NCT00014625
E7070 in Treating Patients With Stage IV Melanoma treatment 2 completed NCT00014456
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors treatment 1 completed NCT00019175
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma treatment 1 completed NCT00019019
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas treatment 1 completed NCT00020839
Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain treatment 3 terminated NCT00016263
Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma treatment 3 completed NCT00019383
Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma treatment 2 completed NCT00019487
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma treatment 2 completed NCT00006237
S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma treatment 3 completed NCT00006385
Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma treatment 2 completed NCT00006233
Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma treatment 2 completed NCT00005615
Post-Operative Adjuvant Radiotherapy With Concurrent Interferon-Alfa treatment 1 / 2 completed NCT00006035
Bleomycin With or Without Electroporation Therapy in Treating Patients With Stage III or Stage IV Melanoma treatment 1 unknown_status NCT00005961
O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma treatment 2 completed NCT00006022
Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer treatment 1 completed NCT00005971
Flavopiridol in Treating Patients With Metastatic Malignant Melanoma treatment 2 completed NCT00005633
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma treatment 1 completed NCT04062032
Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma prevention 2 completed NCT00004153
Detection of Melanoma Markers in Lymph Nodes or Peripheral Blood of Patients With Melanoma No drug interventions diagnostic Not Available completed NCT00004148
Vaccine Therapy in Treating Patients With Unresectable Metastatic Melanoma No drug interventions treatment 1 completed NCT00005052
Vaccine Therapy in Treating Patients With Primary Stage II Melanoma No drug interventions treatment 3 unknown_status NCT00003828
S9804: Vinorelbine in Treating Patients With Stage IV Melanoma treatment 2 completed NCT00004016
Interferon Gamma in Treating Patients With Recurrent or Metastatic Melanoma or Other Solid Tumors treatment 1 completed NCT00004025
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma treatment 1 / 2 unknown_status NCT00002947
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer No drug interventions treatment 1 terminated NCT00003641
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma treatment 3 active_not_recruiting NCT00003224
Vaccine Therapy in Treating Patients With Metastatic Melanoma treatment 1 completed NCT00003715
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma treatment 2 terminated NCT00002763
High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma treatment 3 unknown_status NCT00003339
Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma treatment 2 completed NCT00003911
S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases No drug interventions treatment 2 terminated NCT00002845
Interleukin-2 in Treating Patients With Metastatic Melanoma treatment 2 unknown_status NCT06299878
MelPRO-0322 (CRISTINA Trial) [miCrobiome pRedIctS aPD1 effecTivnes In melaNoma pAtietns] No drug interventions Not Available Not Available recruiting NCT06377111
A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma treatment 1 recruiting NCT06254547
Leaderboard Influence on Self-Regulated Training in a Gamified Dermoscopy Training App No drug interventions diagnostic Not Available recruiting NCT05986331
Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma treatment 3 active_not_recruiting NCT05649683
Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors No drug interventions other Not Available recruiting NCT05655312
MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma No drug interventions treatment 1 / 2 recruiting NCT05279027
Zr89 + PET Companion Trial diagnostic 0 enrolling_by_invitation NCT04901988
Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION treatment 2 / 3 terminated NCT04990479
Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma No drug interventions treatment 1 active_not_recruiting NCT04200040
A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients treatment 2 unknown_status NCT04079166
SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study) treatment 2 recruiting NCT03740503
Genomic Investigation of Unusual Responders No drug interventions Not Available Not Available recruiting NCT04688749
Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage No drug interventions Not Available Not Available terminated NCT03643289
Predicting Response to Immunotherapy for Melanoma With Gut Microbiome and Metabolomics No drug interventions Not Available Not Available unknown_status NCT03581188
Patient-led Surveillance Compared to Clinician-led Surveillance in People Treated for Localised Melanoma. No drug interventions prevention Not Available completed NCT03508297
Reflectance Confocal Microscopy to Diagnose MM & LM No drug interventions Not Available Not Available completed NCT04550000
Sample Collection Study in Patients With Suspected Melanoma Utilizing DermTech's Non-invasive Adhesive Patch Biopsy Kits No drug interventions Not Available Not Available completed NCT05578872
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). treatment 1 / 2 recruiting NCT05569707
MR Lymphography and Magnetic Sentinel Lymph Node Biopsy in Melanoma Patients No drug interventions diagnostic Not Available not_yet_recruiting NCT05854589
Effect of Topical Application of Hypertonic Saline on Melanoma on Its Sizes and Number. treatment 2 not_yet_recruiting NCT05751928
A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma treatment 3 recruiting NCT04301011
Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors treatment 1 / 2 terminated NCT03136783
New Tumor Models in Three Dimensions and in a Human Skin Environment for Personalized Melanoma Therapy No drug interventions other Not Available unknown_status NCT03291002
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC treatment 1 unknown_status NCT03246412
Nevus Doctor Clinical Decision Support for GPs No drug interventions diagnostic Not Available completed NCT03130569
Skin Health Online for Melanoma: Better Risk Assessment No drug interventions other Not Available completed NCT05432193
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) treatment 1 active_not_recruiting NCT03233828
Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2 prevention 3 terminated NCT01176474
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma treatment 1 completed NCT01082198
Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes No drug interventions treatment 1 / 2 unknown_status NCT00976573
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma treatment 2 completed NCT00897520
Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy Not Available Not Available completed NCT00811759
Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma treatment 1 / 2 unknown_status NCT00755976
Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma treatment 2 completed NCT00661336
A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma treatment 1 withdrawn NCT00704938
Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer treatment 2 terminated NCT00700882
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery treatment 2 completed NCT00705640
Vaccine Therapy in Treating Patients With Advanced Melanoma treatment 1 completed NCT00626405
Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery treatment 2 completed NCT00667901
Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery treatment 1 terminated NCT00672321
Answering Questions About Vitamin D Supplementation and Sun Exposure in Patients Who Have Undergone Surgery for Stage IB, Stage II, or Stage IIIA Melanoma No drug interventions Not Available Not Available unknown_status NCT00563823
Vatalanib in Treating Patients With Metastatic Cutaneous Melanoma That Cannot be Removed by Surgery treatment 2 completed NCT00553683
Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer treatment 1 / 2 unknown_status NCT00540969
Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases No drug interventions treatment 3 terminated NCT00568451
Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma treatment 2 terminated NCT00526149
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors treatment 2 completed NCT00521001
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery treatment 2 completed NCT00512889
Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma No drug interventions treatment 1 completed NCT00462982
Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma treatment 2 completed NCT00470015
Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma treatment 1 completed NCT00470379
Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery treatment 0 completed NCT00492505
Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma treatment 2 unknown_status NCT00453050
Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin treatment 1 completed NCT00436410
Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer treatment 0 completed NCT00403377
Investigation of a Behavioral Substitute for Sunbathing No drug interventions Not Available 1 / 2 completed NCT00416988
Educational Program in Skin Self-Examination To Detect Melanoma in Healthy Participants No drug interventions prevention Not Available completed NCT00398073
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma No drug interventions treatment 1 completed NCT00391300
Bioelectric Field Imaging in Diagnosing Melanoma and Other Skin Cancers in Patients With Skin Lesions No drug interventions diagnostic 1 unknown_status NCT00390338
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma No drug interventions treatment 1 completed NCT00334776
Vaccine Therapy in Treating Patients With Metastatic Melanoma treatment 2 completed NCT00357461
Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma treatment 2 withdrawn NCT00324623
Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma treatment 1 completed NCT00317759
Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV Melanoma treatment 1 completed NCT00295906
Computer-Based Continuing Education for Doctors in Examination and Counseling of Patients on Skin Cancer or Weight Control No drug interventions Not Available Not Available unknown_status NCT00324727
Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma treatment 3 completed NCT00093678
Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer supportive_care Not Available withdrawn NCT00138229
Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma treatment 2 terminated NCT00107159
Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma No drug interventions treatment 2 completed NCT00101166
Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma No drug interventions treatment 2 completed NCT00096382
Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma treatment 2 completed NCT00098553
Everolimus in Treating Patients With Stage IV Melanoma treatment 2 completed NCT00128583
Vaccine Therapy in Treating Patients With Malignant Melanoma No drug interventions treatment 2 unknown_status NCT00104897
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma treatment 2 completed NCT00072345
Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma treatment 2 completed NCT00091338
Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma treatment 1 completed NCT00086866
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery No drug interventions treatment 2 unknown_status NCT00082914
Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer treatment 2 completed NCT00079144
Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma treatment 2 completed NCT00071981
Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma treatment 2 completed NCT00084656
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma treatment 2 completed NCT00072085
Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma treatment 2 completed NCT00085423
Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma treatment 2 completed NCT00085397
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma treatment 2 unknown_status NCT00068666
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System treatment 2 terminated NCT00062036
Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma treatment 1 / 2 completed NCT00089206
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery treatment 2 completed NCT00089193
Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma treatment 2 completed NCT00039572
Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain treatment 1 / 2 completed NCT00045357
Biological Therapy in Treating Patients With Metastatic Melanoma No drug interventions treatment 1 completed NCT00019721
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma treatment 2 completed NCT00027742
Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma treatment 2 completed NCT00020397
Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma treatment 2 completed NCT00023647
Vaccine Therapy in Treating Patients With Stage IV Melanoma No drug interventions treatment 1 completed NCT00022438
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment treatment 2 completed NCT00025181
Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery treatment 1 completed NCT00021164
Vaccine Therapy in Treating Patients With Metastatic Cancer treatment 2 completed NCT00017355
Vaccine Therapy in Treating Patients With Metastatic Melanoma treatment 1 unknown_status NCT00010309
Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma treatment 1 / 2 unknown_status NCT00016055
Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma treatment 1 unknown_status NCT00005875
Nitrocamptothecin in Treating Patients With Metastatic Melanoma treatment 2 completed NCT00006368
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer No drug interventions treatment 1 completed NCT00006249
Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma treatment 3 unknown_status NCT00005815
Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma treatment 1 / 2 completed NCT00006113
Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma treatment 2 terminated NCT00005968
Irofulven in Treating Patients With Stage IV Melanoma treatment 2 completed NCT00005610
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung treatment 2 completed NCT00004152
PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma No drug interventions diagnostic 2 completed NCT04040114
Improving Skin Cancer Management With Artificial Intelligence (04.17 SMARTI) No drug interventions diagnostic Not Available completed NCT00003747
Carboplatin and Temozolomide in Treating Patients With Unresectable or Metastatic Melanoma treatment 1 unknown_status NCT00004184
Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma treatment 1 / 2 completed NCT00004065
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer treatment 1 completed NCT00002781
Boron Neutron Capture Therapy in Treating Patients With Stage III Melanoma treatment 1 unknown_status NCT00003568
Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma treatment 2 completed NCT00003274
Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery treatment 2 completed NCT00003989
ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma treatment 2 completed NCT00002952
Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma treatment 1 / 2 completed NCT00003308
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma No drug interventions treatment 2 completed NCT00003346
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma treatment 2 completed NCT00003362
Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma treatment 2 completed NCT00003556
Vaccine Therapy in Treating Patients With Melanoma No drug interventions treatment 1 completed NCT00002892
Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent Melanoma treatment 3 completed NCT00002973
Melphalan and Whole-Body Hyperthermia in Treating Patients With Advanced Melanoma treatment 2 completed NCT00003091
High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma treatment 2 completed NCT00003897
Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma treatment 1 completed NCT00003802
Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma treatment 2 completed NCT00002669
Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma treatment 2 completed NCT00003792
Vaccine Therapy in Treating Patients With Metastatic Melanoma treatment 1 completed NCT00002455
Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma No drug interventions treatment 3 unknown_status NCT00002754
Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors No drug interventions treatment 1 completed NCT00002733
Biological Therapy in Treating Patients With Metastatic Cancer treatment 2 completed NCT00003027
Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma treatment 3 completed NCT00003060
Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma treatment 1 terminated NCT06400550
Identification of Metabolic Phenotypes Associated With Melanoma Metastasis No drug interventions Not Available Not Available recruiting NCT05492682
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer treatment 1 recruiting NCT05402046
Clinical vAlidation of a MobilE appLication ("ProRodinki") in the Assessment of the maLignant skIn neoplAsms No drug interventions diagnostic Not Available unknown_status NCT05307289
Study of Alterations in Tumor Metabolism Associated With the Development of Immunotherapy Resistance in Melanoma No drug interventions basic_science Not Available recruiting NCT04904120
Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy No drug interventions diagnostic 1 completed NCT06439979
Rural Adult and Youth Sun Protection Study No drug interventions prevention Not Available recruiting NCT04099446
A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer No drug interventions Not Available Not Available withdrawn NCT03972046
Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma treatment 2 withdrawn NCT03767348
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab treatment 2 recruiting NCT03621462
Elucid Labs AIDA™ - Labelled Image Acquisition Protocol No drug interventions diagnostic Not Available unknown_status NCT03518229
Pilot Study of Intervention to Reduce Sunburns in Melanoma Survivors No drug interventions prevention Not Available withdrawn NCT03509467
Using MC1R Genotype to Impact Melanoma Risk Behavior No drug interventions prevention Not Available completed NCT04834167
OneDoc Picopulse™ for the Treatment of Melasma Among Malaysian Women No drug interventions treatment Not Available completed NCT03405155
Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery treatment 2 active_not_recruiting NCT03315468
French Clinical Datbase of Melanoma Patients (RIC-Mel) No drug interventions Not Available Not Available recruiting NCT03294330
SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer diagnostic 3 completed NCT02652455
Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma treatment 0 completed NCT01489423
Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim No drug interventions Not Available Not Available completed NCT01388569
Biomarkers in Blood Samples From Patients With Stage IV Melanoma Previously Treated With Sargramostim No drug interventions Not Available Not Available completed NCT01018004
Comparing Follow-Up Schedules in Patients With Newly Diagnosed Stage IB or Stage II Melanoma No drug interventions Not Available Not Available unknown_status NCT00991991
Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma No drug interventions Not Available Not Available terminated NCT00974610
Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer. No drug interventions Not Available Not Available completed NCT00937781
Study of Tumor Tissue From Patients With Melanoma Treated on Clinical Trial EST-1690 No drug interventions Not Available Not Available completed NCT00897546
Biomarkers to Predict Response to Interferon Therapy in Patients With Melanoma No drug interventions Not Available Not Available completed NCT00897481
Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy No drug interventions Not Available Not Available unknown_status NCT00866840
Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery treatment 2 completed NCT00798629
Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured treatment 1 completed NCT00757614
Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom No drug interventions Not Available Not Available unknown_status NCT00658892
Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma No drug interventions treatment 1 completed NCT00602576
Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma treatment 2 completed NCT00568048
Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery treatment 2 completed NCT00568763
Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma treatment 1 completed NCT00565968
Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg treatment 1 completed NCT00492440
Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer treatment 1 terminated NCT00445965
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer No drug interventions treatment 2 completed NCT00450372
Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery treatment 2 completed NCT00398450
Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma treatment 1 completed NCT00346008
Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members No drug interventions Not Available Not Available completed NCT00313508
Dendritic Cell Vaccination During Lymphoid Reconstruction treatment 1 completed NCT00316901
Positron Emission Tomography and CT Scan in Predicting Response in Patients With Metastatic Melanoma or Kidney Cancer Who Are Undergoing Cellular Adoptive Immunotherapy on a Surgery Branch Clinical Trial No drug interventions diagnostic 2 completed NCT00276835
Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer treatment 0 completed NCT00238329
PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma treatment 2 completed NCT00109863
Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma treatment 2 completed NCT00085462
Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma treatment 1 completed NCT00073892
PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma treatment 1 / 2 completed NCT00091104
Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma treatment 1 completed NCT00085579
Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma treatment 2 withdrawn NCT00090896
CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery No drug interventions treatment 1 completed NCT00091143
Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma treatment 1 completed NCT00089219
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma treatment 1 / 2 completed NCT00058279
Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma treatment 1 / 2 completed NCT00053781
Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma treatment 2 completed NCT00049530
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma treatment 2 completed NCT00053391
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma treatment 1 / 2 completed NCT00049010
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma No drug interventions diagnostic Not Available completed NCT00056134
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma treatment 1 / 2 completed NCT00054535
Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma treatment 2 completed NCT00039234
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver treatment 3 unknown_status NCT00022568
Vaccine Therapy in Treating Patients With Metastatic Melanoma No drug interventions treatment 1 unknown_status NCT00022464
CCI-779 in Treating Patients With Metastatic Melanoma treatment 2 completed NCT00019994
Vaccine Therapy in Treating Patients With Metastatic Melanoma treatment 2 completed NCT00020540
Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer treatment 1 completed NCT00020358
Vaccine Therapy in Treating Patients With Melanoma treatment 2 completed NCT00026520
Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma treatment 2 completed NCT00019669
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma treatment 2 completed NCT00025012
Isotretinoin in Preventing Skin Cancer prevention Not Available completed NCT00118274
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma treatment 1 / 2 completed NCT00007969
Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma treatment 1 / 2 completed NCT00019214
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma treatment 1 / 2 completed NCT00019331
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors treatment 2 completed NCT00017316
Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma treatment 2 completed NCT00017121
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung treatment 1 completed NCT00012064
Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma No drug interventions treatment 1 / 2 completed NCT00070343
Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301 treatment Not Available unknown_status NCT00014092
Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery treatment 2 completed NCT00005943
Gene Therapy in Treating Patients With Metastatic Melanoma treatment 1 completed NCT00005841
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma treatment 1 terminated NCT00005057
Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma treatment 1 completed NCT00006126
Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery treatment 1 withdrawn NCT04066725
Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma prevention 2 completed NCT00004196
Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis treatment 3 completed NCT00004135
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer treatment 2 completed NCT00004244
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma treatment 1 completed NCT00003690
Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors treatment 1 completed NCT00004250
Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery treatment 2 completed NCT00004104
Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma treatment 2 completed NCT00004141
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma treatment 2 completed NCT00004022
Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma treatment 2 completed NCT00003750
Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors treatment 1 completed NCT00003444
Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin treatment 3 completed NCT00003022
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer No drug interventions treatment 1 completed NCT00003222
Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma treatment 2 completed NCT00003601
Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome prevention 2 completed NCT00003665
Vaccine Therapy in Treating Patients With Stage IV Melanoma treatment 1 completed NCT00002767
Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma treatment 3 unknown_status NCT00002817
Vaccine Therapy in Treating Patients With Metastatic Melanoma treatment 1 / 2 unknown_status NCT00002786
Biological Therapy in Treating Patients With Metastatic Melanoma treatment 1 / 2 completed NCT00003229
Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal treatment 1 / 2 completed NCT00002535
Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma treatment 2 completed NCT00002860
SWOG-9430: Surgery in Treating Patients With Metastatic Melanoma No drug interventions treatment 2 completed NCT01477463
Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers prevention Not Available completed NCT02668887
Employment and Quality of Life in Patients With Malignant Melanoma No drug interventions Not Available Not Available completed NCT06014086
Intratumoral PH-762 for Cutaneous Carcinoma No drug interventions treatment 1 recruiting